US20230364173A1 - Synergistic herbal compositions for immunity, cold and cough - Google Patents
Synergistic herbal compositions for immunity, cold and cough Download PDFInfo
- Publication number
- US20230364173A1 US20230364173A1 US18/246,768 US202118246768A US2023364173A1 US 20230364173 A1 US20230364173 A1 US 20230364173A1 US 202118246768 A US202118246768 A US 202118246768A US 2023364173 A1 US2023364173 A1 US 2023364173A1
- Authority
- US
- United States
- Prior art keywords
- glycyrrhizin
- zinc
- extract
- salt
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 260
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 55
- 206010011224 Cough Diseases 0.000 title claims abstract description 40
- 230000036039 immunity Effects 0.000 title claims abstract description 25
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 258
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 254
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 254
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 254
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 254
- 239000004378 Glycyrrhizin Substances 0.000 claims abstract description 236
- 239000000284 extract Substances 0.000 claims abstract description 203
- 150000003839 salts Chemical class 0.000 claims abstract description 159
- 239000011701 zinc Substances 0.000 claims abstract description 113
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 111
- 239000011591 potassium Substances 0.000 claims abstract description 111
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 111
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 109
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 108
- 240000003428 Tinospora crispa Species 0.000 claims abstract description 102
- 239000004615 ingredient Substances 0.000 claims abstract description 97
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 85
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 claims abstract description 80
- 240000004836 Justicia adhatoda Species 0.000 claims abstract description 69
- 229910052751 metal Inorganic materials 0.000 claims abstract description 59
- 239000002184 metal Substances 0.000 claims abstract description 59
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 58
- 235000008397 ginger Nutrition 0.000 claims abstract description 58
- 239000001841 zingiber officinale Substances 0.000 claims abstract description 58
- 150000003751 zinc Chemical class 0.000 claims abstract description 52
- 235000004072 Ocimum sanctum Nutrition 0.000 claims abstract description 50
- 229930000223 plant secondary metabolite Natural products 0.000 claims abstract description 50
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 49
- 235000017807 phytochemicals Nutrition 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 37
- 230000000241 respiratory effect Effects 0.000 claims abstract description 31
- 230000036541 health Effects 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 12
- 235000002639 sodium chloride Nutrition 0.000 claims description 159
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 238000004519 manufacturing process Methods 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 208000024891 symptom Diseases 0.000 claims description 34
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 24
- 230000028993 immune response Effects 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 21
- 239000000969 carrier Substances 0.000 claims description 20
- 239000003085 diluting agent Substances 0.000 claims description 20
- 210000000987 immune system Anatomy 0.000 claims description 20
- 208000037883 airway inflammation Diseases 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 19
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- 201000010105 allergic rhinitis Diseases 0.000 claims description 17
- 230000015788 innate immune response Effects 0.000 claims description 17
- 230000004199 lung function Effects 0.000 claims description 17
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 16
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 14
- 230000004721 adaptive immunity Effects 0.000 claims description 14
- 230000007407 health benefit Effects 0.000 claims description 14
- 230000037125 natural defense Effects 0.000 claims description 14
- 230000003716 rejuvenation Effects 0.000 claims description 14
- 208000003251 Pruritus Diseases 0.000 claims description 13
- 230000007969 cellular immunity Effects 0.000 claims description 13
- 230000004727 humoral immunity Effects 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000011787 zinc oxide Substances 0.000 claims description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 11
- 238000005728 strengthening Methods 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 8
- 239000003729 cation exchange resin Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 claims description 8
- 229960000280 phenindione Drugs 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- -1 fatty acid esters Chemical class 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 6
- 150000004692 metal hydroxides Chemical class 0.000 claims description 6
- 229910044991 metal oxide Inorganic materials 0.000 claims description 6
- 150000004706 metal oxides Chemical class 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 150000002736 metal compounds Chemical class 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Polymers 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000002211 L-ascorbic acid Substances 0.000 claims description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 235000006089 Phaseolus angularis Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 240000007098 Vigna angularis Species 0.000 claims description 2
- 235000010711 Vigna angularis Nutrition 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 235000016213 coffee Nutrition 0.000 claims description 2
- 235000013353 coffee beverage Nutrition 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 235000014510 cooky Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 2
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229940093915 gynecological organic acid Drugs 0.000 claims description 2
- 239000011121 hardwood Substances 0.000 claims description 2
- 235000001497 healthy food Nutrition 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 229920001206 natural gum Polymers 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 235000011962 puddings Nutrition 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 150000004760 silicates Chemical class 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 235000014214 soft drink Nutrition 0.000 claims description 2
- 235000021055 solid food Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 239000011667 zinc carbonate Substances 0.000 claims description 2
- 235000004416 zinc carbonate Nutrition 0.000 claims description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 claims description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 claims description 2
- 229940007718 zinc hydroxide Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 239000011686 zinc sulphate Substances 0.000 claims description 2
- 235000009529 zinc sulphate Nutrition 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 244000136948 Ocimum sanctum Species 0.000 claims 6
- 240000002837 Ocimum tenuiflorum Species 0.000 abstract description 56
- 208000037884 allergic airway inflammation Diseases 0.000 abstract description 15
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 111
- 244000303040 Glycyrrhiza glabra Species 0.000 description 93
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 64
- 108010074328 Interferon-gamma Proteins 0.000 description 56
- 230000005764 inhibitory process Effects 0.000 description 55
- 102100037850 Interferon gamma Human genes 0.000 description 46
- 239000000469 ethanolic extract Substances 0.000 description 43
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 41
- 108010058846 Ovalbumin Proteins 0.000 description 41
- 229940092253 ovalbumin Drugs 0.000 description 41
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 229960001340 histamine Drugs 0.000 description 32
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 32
- 230000007423 decrease Effects 0.000 description 27
- 230000004073 interleukin-2 production Effects 0.000 description 27
- 230000000996 additive effect Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 102000000588 Interleukin-2 Human genes 0.000 description 21
- 108010002350 Interleukin-2 Proteins 0.000 description 21
- 239000000654 additive Substances 0.000 description 20
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 18
- 239000001685 glycyrrhizic acid Substances 0.000 description 18
- 210000003979 eosinophil Anatomy 0.000 description 17
- 210000003630 histaminocyte Anatomy 0.000 description 17
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 239000000401 methanolic extract Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 210000001331 nose Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000000440 neutrophil Anatomy 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 102000008070 Interferon-gamma Human genes 0.000 description 10
- 210000004969 inflammatory cell Anatomy 0.000 description 10
- 229960003130 interferon gamma Drugs 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000013566 allergen Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 201000009240 nasopharyngitis Diseases 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 235000002780 gingerol Nutrition 0.000 description 5
- 150000002617 leukotrienes Chemical class 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- YIICVSCAKJMMDJ-UHFFFAOYSA-N L-vasicine Natural products C1=CC=C2N=C3C(O)CCN3CC2=C1 YIICVSCAKJMMDJ-UHFFFAOYSA-N 0.000 description 4
- YIICVSCAKJMMDJ-SNVBAGLBSA-N Peganine Chemical compound C1=CC=C2N=C3[C@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-SNVBAGLBSA-N 0.000 description 4
- YIICVSCAKJMMDJ-JTQLQIEISA-N Peganine Natural products C1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-JTQLQIEISA-N 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000009285 allergic inflammation Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 229940074774 glycyrrhizinate Drugs 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- XDJMDNAHFNLMKP-UHFFFAOYSA-N Tinospora clerodane Natural products CC12CCC3(O)C(=O)OC(CC3(C)C1C4OC(=O)C2(O)C5OC45)c6cocc6 XDJMDNAHFNLMKP-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940054441 o-phthalaldehyde Drugs 0.000 description 2
- 239000008601 oleoresin Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 229940043517 specific immunoglobulins Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000012607 strong cation exchange resin Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000277911 Alpinia galangal Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 244000025780 Clerodendrum serratum Species 0.000 description 1
- 235000010468 Clerodendrum serratum Nutrition 0.000 description 1
- 102000004405 Collectins Human genes 0.000 description 1
- 108090000909 Collectins Proteins 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241001609693 Cucumis trigonus Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 1
- 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 241000207955 Inula racemosa Species 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 1
- 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 240000009120 Phyllanthus emblica Species 0.000 description 1
- 240000003731 Piper cubeba Species 0.000 description 1
- 235000002711 Piper cubeba Nutrition 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 235000001254 Solanum anguivi Nutrition 0.000 description 1
- 244000070669 Solanum ferox Species 0.000 description 1
- 235000018253 Solanum ferox Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 244000191422 Terminalia bellirica Species 0.000 description 1
- 235000012023 Terminalia bellirica Nutrition 0.000 description 1
- 241000001522 Terminalia chebula Species 0.000 description 1
- 235000011517 Terminalia chebula Nutrition 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 210000004704 glottis Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001927 high performance liquid chromatography-inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229960002808 pholcodine Drugs 0.000 description 1
- GPFAJKDEDBRFOS-FKQDBXSBSA-N pholcodine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCCN1CCOCC1 GPFAJKDEDBRFOS-FKQDBXSBSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012608 weak cation exchange resin Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the invention relates to synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for obtaining at least one health benefit selected from improving immunity and improving respiratory health that include allergic airway inflammation, cold and cough.
- Immunity is the body's natural defense system against various bacterial/viral/fungal infections, diseases, and different environmental stimuli. Primarily, host immunity is classified into innate and adaptive immune responses. Innate immune responses are rapid and non-specific to pathogens, which are mediated by innate immune cells such as myeloid cells, natural killer (NK) cells, innate lymphoid cells, and humoral systems such as defensins and complement systems. Adaptive immune responses are slower but specific to the infections with the recruitment of B- and T-lymphocytes and generation of long-lived immunological memory.
- innate immune cells such as myeloid cells, natural killer (NK) cells, innate lymphoid cells, and humoral systems
- Adaptive immune responses are slower but specific to the infections with the recruitment of B- and T-lymphocytes and generation of long-lived immunological memory.
- Respiratory health The lungs are constantly exposed to the external environment and come in contact with potential air-borne pathogens, allergens, and environmental pollutants. This constant exposure requires an effective and fast-acting immune system.
- the pulmonary immune system contains a broad armamentarium of cellular and humoral defense mechanisms in the airways.
- the coordinated and complex interplay between the resident airway epithelial cells and infiltrating immune cells along with the secretions of defensins, mucins, or collectins shape the outcome of host-pathogen, host-allergen, host-particle interactions within the airway microenvironment.
- chemokines CCL-2, CCL-20
- cytokines IL-1 ⁇ , IL-1 ⁇
- lipid mediators eicosanoids/leukotrienes
- Airway inflammation including asthma and allergic rhinitis, is the common chronic respiratory illness worldwide. Low temperature, accompanying low air humidity, air pollutants (such as pollen, dust, etc.) affect the respiratory epithelium and induce hyper responsiveness (bronchial allergy) and narrowing of the respiratory airways. Poor air quality and cold air also influence chronic airway inflammation, which is likely to aggravate respiratory symptoms. Epidemiological studies have shown that respiratory symptoms such as wheezing, cough, runny, stuffy nose, congestion, phlegm (a byproduct of inflammation in the sinuses and the lungs) are common among adults and children. A decline in lung function and a high prevalence of respiratory symptoms in the cold indoor environment have also been reported.
- Allergic airway inflammation is characterized by reversible airway obstruction, airway hyper-responsiveness (AHR), infiltration of eosinophils and type 2 T-cells (that activate eosinophils and mast cells) into the airway submucosa, mucus hypersecretion, and airway remodeling.
- AHR airway hyper-responsiveness
- eosinophils and type 2 T-cells that activate eosinophils and mast cells
- mucus hypersecretion and airway remodeling.
- the allergen-specific immunoglobulins of the IgE class bound to the surfaces of basophils and mast cells present in the sub-epithelial layer of the airways. These bound IgE molecules immediately release leukotrienes, prostaglandins, and histamine.
- chemokines stimulate the recruitment of eosinophils, macrophages, neutrophils, and T-lymphocytes in the airways.
- Common cold (synonyms: acute coryza, acute viral nasopharyngitis) is a highly contagious viral disease of the upper respiratory tract involving the nose, sinuses, pharynx, and larynx. At least 200 identified viruses are capable of causing the common cold. Among these, rhinoviruses, coronaviruses, parainfluenza viruses, respiratory syncytial virus, adenoviruses, and enteroviruses are common. The histologic effects of infection vary from mild to severe epithelial destruction. The infection causes vasodilation and hypersecretion. The common clinical symptoms include nasal congestion, nasal discharge, postnasal drip (PND), throat clearing, sneezing, and cough.
- PND postnasal drip
- Cough is a forced expulsive maneuver, usually against a closed glottis and which is associated with a characteristic sound.
- An acute cough is defined as one lasting less than 3 weeks. It is the commonest symptom associated with acute exacerbations and hospitalizations with asthma and chronic obstructive pulmonary disease (COPD).
- Chronic cough is defined as one lasting more than 8 weeks. Most patients present with a dry or minimally productive cough. Because of the variable and episodic nature of acute cough, cough suppressants such as dextromethorphan, menthol, sedative antihistamines, codeine or pholcodine are used.
- Patent publication U.S. Pat. No. 6,979,471B1 disclosed a composition comprising a bio-enhancer or bioavailability facilitator selected from the group consisting of isolated and purified glycyrrhizic acid, isolated and purified glycyrrhizin or mixtures thereof in a concentration of about 1 ⁇ g/ml and an agent selected from one or more nutraceuticals, antibiotics, anti-infective agents, and anti-cancer agents.
- a bio-enhancer or bioavailability facilitator selected from the group consisting of isolated and purified glycyrrhizic acid, isolated and purified glycyrrhizin or mixtures thereof in a concentration of about 1 ⁇ g/ml and an agent selected from one or more nutraceuticals, antibiotics, anti-infective agents, and anti-cancer agents.
- Another patent publication US20030228383A1 disclosed a herbal composition for the treatment of chronic respiratory disorders such as cold, cough, allergic asthma, seasonal allergic rhinitis, pharyngitis, laryngitis comprises extracts derived from Ayurvedic plants selected from the Ocimum sanctum, Glycyrrhiza glabra, Curcuma longa, Zingiber officinale, Adhatoda vasika, Solanum indicum, Saussurea lappa, Piper cubeba, Terminalia bellirica, Aloe barbadensis, Inula racemosa, Clerodendrum serratum, Solanum xanthocorpum, Pipper longum, Alpinia galangal, Terminalia chebula, Emblica officinalis and a process for preparing the same.
- EP1529445B1 disclosed a dietary supplement composition
- a dietary supplement composition comprising an active ingredient, a vegetable protein containing carrier, a vegetable source for sugar, a vegetable source for fat, and salt, wherein the active ingredient is constituted by a mixture of 14-26% of Zingiber officinalis, 14-26% of Piper longum, 14-26% of Piper nigrum, 14-26% of Cucumis trigonus , and 14-26% of Glycyrrhiza glabra.
- Patent publications CN1010373B, CN104530177B, CN105541956A and CN1120172C disclosed various process techniques for the preparation of licorzinc (zinc glycyrrhizinate) from glycyrrhizic acid.
- synergistic herbal compositions comprising a first ingredient zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra ; and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum are not known in the literature.
- the main object of the present invention is to provide synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough,
- Another objective of the invention is to provide method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing the said human with an effective dose of a composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinal
- Yet another objective of the invention is to provide the use of a synergistic herbal composition
- a synergistic herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy
- Another aspect of the invention provides synergistic herbal compositions comprising a first ingredient, Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- the invention provides a process for the preparation of the compositions comprising a first ingredient, Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- the invention provides method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing the said human with an effective dose of a composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale
- the invention provides the use of a synergistic herbal composition
- a synergistic herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural
- glycyrrhizin and glycyrrhizic acid are the same and are interchangeable.
- the statements “zinc/potassium double salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizic acid and zinc/potassium double salt of glycyrrhizinate” made in the specification convey the same meaning and are interchangeable.
- zinc salt of glycyrrhizin zinc salt of glycyrrhizic acid and zinc salt of glycyrrhizinate
- potassium salt of glycyrrhizin potassium salt of glycyrrhizic acid and potassium salt of glycyrrhizinate
- any of the words, “including”, “includes”, “comprising”, and comprises” mean “including without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items.
- the terms “metal salt”, “metal complex” and “metal chelate” also convey the same meaning and are used interchangeably in the specification. Unless specified otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- the source of the herbs used in the invention is as follows:
- Glycyrrhiza glabra G. glabra is a widely used and extensively researched medicinal plant around the world. In Ayurveda, it is used for treating coughs, colds, and chills. In traditional medicine, its roots have been used for treating chest and lung diseases, pneumonia, bronchitis, arthritis, bronchial asthma, kidney diseases, heart diseases, gastric ulcer, mouth ulcers, coughs, swellings, excessive salivation, fluid retention, low blood pressure, allergies, catarrhs of the upper respiratory tract, liver toxicity, hyperglycemia, and certain viral infections. Glycyrrhiza glabra contains several phytochemical constituents and out of which glycyrrhizin (glycyrrhizic acid) is the major active phytochemical.
- glycyrrhizin glycyrrhizic acid
- Glycyrrhizin also called as glycyrrhizic acid, is a triterpenoid saponin obtained from the root and rhizome extracts of Glycyrrhiza glabra (Licorice).
- Glycyrrhizic acid is the major characteristic constituent of licorice, which is primarily responsible for its pharmacological activities and sweet taste. It is widely used in traditional Indian, Chinese, and Vietnamese medicinal preparations. Glycyrrhizic acid is also used as a sweetener in many applications, and it is reported to be 30-50 times sweeter than sucrose.
- glycyrrhizin is used as an anti-inflammatory, anti-thrombin, anti-tumor, anti-ulcer, anti-allergic, anti-oxidant, anti-viral agent, and also for treating chronic hepatic diseases.
- the chemical structure of glycyrrhizin is shown below (FIG. 1).
- Zinc is the second most abundantly distributed trace element in the body after iron. It is found only in modest amounts in varieties of food, such as beef, poultry, seafood, and grains. It is needed for wound healing, sense of taste and smell, DNA synthesis, and it supports normal growth and development during pregnancy, childhood, and adolescence. Zinc deficiency in the body can lead to a variety of health-related problems. Zinc is essential for the biological activity of over 300 enzymes that aid in metabolism, digestion, nerve function, and many other processes. Zn is known to be important in immune function, DNA and protein production, and cell division.
- Potassium is the essential mineral needed in higher quantity than any other metal, with a requirement of up to 3500 mg per day. Potassium plays a vital role in blood pressure regulation, carbohydrate metabolism, and fluid balance. The functions of potassium and sodium in living organisms are quite different. Potassium is the major cation present inside the animal cells, while sodium is the major cation present outside the animal cells, and they play a critical role in maintaining membrane potential. As sodium consumption rises, increased potassium is needed to balance the effect of sodium on blood pressure.
- Zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra is not known in the literature.
- the present invention provides synergistic herbal compositions comprising a first ingredient zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra ; and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda and Ocimum sanctum ; further containing optionally at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- the inventors achieved the preparation of zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra ; by two methods, (i) neutralization of G. glabra extract with zinc oxide and potassium carbonate; and (ii) G. glabra extract was purified by cation exchange resin and the glycyrrhizin thus obtained was neutralized with zinc oxide and potassium carbonate.
- the 50% aqueous ethanol extract of Glycyrrhiza glabra was neutralized with metal oxide such as zinc oxide followed by metal carbonate such as potassium carbonate or metal hydroxide such as potassium hydroxide or mixtures thereof to yield zinc/potassium double salt of glycyrrhizin (Gly-2).
- metal oxide such as zinc oxide
- metal carbonate such as potassium carbonate or metal hydroxide
- the extract was analyzed for glycyrrhizin by the HPLC method of analysis and found that the extract contains 14.88% of glycyrrhizin.
- Zinc and potassium were estimated by ICP mass and found that the extract contains 0.9% of zinc and 2.5% of potassium (Example 1).
- purified glycyrrhizic acid was obtained by purification of 50% aqueous ethanol extract of Glycyrrhiza glabra root through a cation exchange resin column.
- the glycyrrhizic acid thus obtained was neutralized with metal oxide followed by metal carbonate or metal hydroxide or mixtures thereof to yield zinc/potassium double salt of glycyrrhizin (Gly-3).
- Salt formation The chemical structure of glycyrrhizic acid contains three carboxylic acid groups, which are capable of forming salts with bases.
- Glycyrrhiza glabra extract containing glycyrrhizic acid when treated with metal oxides, metal hydroxides, and metal carbonates etc. forms metal salt of glycyrrhizic acid.
- neutralization of Glycyrrhiza glabra extract with zinc oxide and potassium carbonate followed by filtration of the solution to remove water insoluble and unreacted zinc oxide gave Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizic acid.
- the presence of zinc and potassium by ICP-MS analysis of the extract clearly indicates the formation of salt.
- Interferon- ⁇ is a cytokine produced mainly by Th1 lymphocytes in response to microbes, intracellular parasites, viruses, and autoimmune reactions.
- Interferon- ⁇ (IFN- ⁇ ) has been shown to have profound effects on both innate and adaptive immunity, which contribute to host protection.
- IFN- ⁇ is produced by adaptive CD4+ Th1 T cells, CD8+ cytotoxic T cells, natural killer (NK) cells, B cells, NKT cells, and innate professional antigen-presenting cells (APCs) [monocyte/macrophage, dendritic cells (DC)].
- IFN- ⁇ has a critical role in recognizing and eliminating pathogens as it can coordinate a plethora of anti-microbial and anti-viral functions through cell-mediated immunity. It can enhance the antigen recognizing capacity of APCs and amplify their antigen presentation to the T cells, subsequently increasing the production of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNIs) and induce anti-viral responses.
- ROS reactive oxygen species
- RNIs reactive nitrogen intermediates
- INF- ⁇ treatment protects neurons from varicella-zoster virus and limit Hepatitis C virus proliferation in HIV patients.
- compounds promoting INF- ⁇ production would be important to boost the host immune system and also for improving respiratory health.
- Interleukin-2 was one of the first cytokines discovered. It can promote T cell proliferation and differentiation in vitro and plays a crucial role during antigen-driven clonal expansion of T cells in vivo. With respect to immune activation in vivo, IL-2 has a role in the proliferation and survival of T cells and differentiation of T cells into effector T cells. In the case of chronic infection, IL-2 is also an important factor in generating memory T cells that can undergo secondary expansion when they re-encounter the antigen. Alternatively, IL-2 can promote activation-induced cell death (AICD) of the T cells, down-regulating the immune response after the clonal expansion of antigen-specific T cells.
- AICD activation-induced cell death
- IL-2 can also prime CD8+ T cells with non-infectious immunogens. Conversely, very high levels of IL-2 can bind to CD25 and differentiate the T cells into regulatory T cells (Tregs), which will suppress the excessive immune response. In this regard, compounds promoting IL-2 production would be important to boost the host immune system.
- Tregs regulatory T cells
- Leukotriene B 4 is a metabolite of the 5-lipoxygenase pathway and was discovered in 1979.
- the leukotrienes (LTs) a family of proinflammatory lipid mediators, play an important role in the pathogenesis of allergic inflammation and are divided into two classes: the chemoattractant LTB 4 and the spasmogenic cysteinyl LTs [CysLTs: LTC 4 , LTD 4 , and LTE 4 ].
- LTB 4 cannot be stored and released, but it is synthesized from arachidonic acid in activated innate immune cells such as granulocytes, macrophages, and mast cells following several enzymatic steps.
- LTB 4 Three distinct receptors for LTB 4 are PPAR ⁇ , BLT1, and BLT2.
- LTB 4 is closely related to the pathogenesis of several allergic diseases, including allergic rhinitis. Allergen-induced nasal congestion and increased LTB 4 levels in nasal lavage fluid of patients with allergic rhinitis were significantly decreased by treatment with LTB 4 antagonists.
- Leukotrienes are potent inflammatory mediators of chemotaxis, bronchoconstriction, and vascular permeation, which are predominately produced by leucocytes but also by other inflammatory immune cells and in cough-associated eosinophilic inflammation, blockade of leukotriene receptors has been shown to be efficacious in cold and cough treatment.
- Histamine is an active substance that plays a major role in an allergic reaction, dilating blood vessels and increasing the permeability of vessel walls. It exerts its effects by binding to histamine receptors (H1, H2, H3, and H4) on cells' surfaces.
- the H1 histamine receptor plays an important role in allergic response and is widely distributed in smooth muscle, where its activation causes vasoconstriction. Activation of the H1 receptor also causes blood vessel dilation, increased vessel permeability, stimulation of sensory nerves in the airways, and bronchoconstriction. In addition, activation of this receptor promotes the chemotaxis of eosinophils, which can lead to nasal congestion, sneezing, and rhinorrhea.
- Antihistamines are effectively used for the treatment of some allergic disorders, which act by competing with histamine released from mast cells in mucous membranes for receptor sites in target organs.
- Upper respiratory tract disorders are the most common causes of chronic and acute cough in humans. It has recently been proposed that the host of upper respiratory disorders that frequently cause cough to be collectively described as upper airway cough syndrome (UACS).
- UACS upper airway cough syndrome
- a possible mechanism by which antihistamines could inhibit pathologic cough is by binding to nonhistaminergic receptors in the central nervous system that control cough excitability which could further regulate nasal mucus secretion.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin Gly-2
- G. glabra extract containing zinc salt of glycyrrhizin Gly-4
- G. glabra extract containing potassium salt of glycyrrhizin Gly-5
- G. glabra extract containing salts potently elevated the levels of said cytokines; and showed greater improvements in the production of IFN- ⁇ and IL-2 compared to the regular G. glabra extract.
- IFN ⁇ production activity of G. glabra extract containing zinc/potassium double salt of glycyrrhizin showed an 18.18% increase in IFN ⁇ production at 10 ⁇ g/mL
- G. glabra regular extract (Gly-1) showed a 13.86% increase in IFN ⁇ production at 10 ⁇ g/mL.
- glabra extract containing zinc salt of glycyrrhizin (Gly-4) and G. glabra extract containing potassium salt of glycyrrhizin (Gly-5) also showed higher efficacy in IFN ⁇ production activity than the G. glabra direct extract (Gly-1).
- IL-2 production assay of G. glabra extract containing zinc/potassium double salt of glycyrrhizin showed a 12.93% increase in IL-2 production at 10 ⁇ g/mL
- G. glabra regular extract (Gly-1) showed a 7.96% increase in IL-2 production at 10 ⁇ g/mL.
- other salts also showed higher efficacy in IL-2 production activity than the G. glabra regular extract (Gly-1).
- the present invention provides improved Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin; wherein Glycyrrhiza glabra extract comprises glycyrrhizin in the range of 2.0-50%, zinc in the range of 0.1-5.0% and potassium in the range of 0.1-10.0%.
- compositions comprising Glycyrrhiza glabra extract containing metal salts of glycyrrhizin in combination with at least one ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; to explore the efficacy of these compositions in improving immunity and respiratory health.
- T. cordifolia dried stem was pulverized, and the powder was extracted with water, and the extract was concentrated to obtain water extract (T.C-1).
- T. cordifolia dried stem powder was extracted with other solvents such as 50% aq ethanol and ethanol to obtain 50% aq ethanol extract (T.C-2) and ethanol extract (T.C-3), respectively.
- These extracts of T. cordifolia were standardized to 8-hydroxytinosporide by the analytical HPLC method of analysis, and the results are summarized in Table 4.
- composition-2 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in the ratio of 2:1
- composition-2A comprising G. glabra extract (Gly-1) and T. cordifolia water extract (T.C-1) in the ratio of 2:1, a comparative composition without salt
- composition-7 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1
- composition-7A comprising G.
- compositions comprising Glycyrrhiza glabra extract containing zinc/potassium salt of glycyrrhizin or regular extract and Tinospora cordifolia water extract or Zingiber officinale oleoresin-2 % Increase in % Increase in IFN- ⁇ IL-2 Comp production at production at # Composition Description 10 ⁇ g/mL 10 ⁇ g/mL Comp- G. glabra extract (Gly-1) and 16.81 10.63 2A T. cordifolia water extract (T.C-1) in the ratio of 2:1 Comp- G. glabra extract containing 23.18 15.96 2 zinc/potassium salt of glycyrrhizin (Gly-2) and T.
- cordifolia water extract in the ratio of 2:1 Comp- G. glabra extract (Gly-1) and 18.23 9.94 7A Z. officinale oleoresin-2 (Z.O- 2) in the ratio of 3:1 Comp- G. glabra extract containing 22.87 15.86 7 zinc/potassium salt of glycyrrhizin (Gly-2) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1
- IFN- ⁇ production of the composition-2 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in the ratio of 2:1 showed 23.18% increase at 10 ⁇ g/mL. While similar composition with regular G. glabra extract without salt (comp-2A) showed a 16.81% increase in IFN- ⁇ production at 10 ⁇ g/mL, this is a surprising and unexpected result for enhancement of IFN- ⁇ production activity of the composition-2 compared to the corresponding comparative composition without salt (Table 2).
- composition-2 showed a 15.96% increase at 10 ⁇ g/mL
- composition without salt (comp-2A) showed a 10.63% increase in IL-2 production at 10 ⁇ g/mL.
- composition-7 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1 also showed surprisingly higher efficacy in improving IFN- ⁇ and IL-2 production than the composition without salt (comp-7A).
- the compositions comprising G.
- glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) with other herbal extracts such as T. cordifolia or Z. officinale showed better efficacy in increasing production of IFN- ⁇ and IL-2 when compared to the corresponding compositions without salt.
- compositions (C1-C44) were tested for their efficacy in increasing the production of IFN- ⁇ , IL-2, and inhibition of LTB 4 , Histamine release in in-vitro cellular models compared to the corresponding individual ingredients. Unexpectedly, these compositions showed synergistic activity.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 ⁇ g/mL concentration and Tinospora cordifolia water extract (T.C-1) at 2.5 ⁇ g/mL concentration showed 13.64% and 3.01% increase in IFN- ⁇ production, respectively.
- the composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 ⁇ g/mL showed a 23.49% increase in IFN- ⁇ production, which is significantly higher than the additive effect of 16.65% (13.64%+3.01%) calculated from the increase in IFN- ⁇ production showed by the corresponding individual ingredients (Table 8).
- compositions 2-44 comprising G. glabra extract containing zinc salt of glycyrrhizin or potassium salt of glycyrrhizin or zinc/potassium double salt of glycyrrhizin and one ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; also exhibited synergism when compared to the increase in IFN- ⁇ production shown by each of their corresponding individual ingredient concentrations as summarized in Tables 8-12.
- compositions (C1-C44) also showed greater increases in IL-2 production than the corresponding individual ingredients.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 ⁇ g/mL concentration and T. cordifolia water extract (T.C-1) at 2.5 ⁇ g/mL concentration showed 9.70% and 2.43% increase in IL-2 production, respectively.
- composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 ⁇ g/mL showed a 16.23% increase in IL-2 production, which is significantly higher than the additive effect of 12.13% (9.70%+2.43%) calculated from the increase in IL-2 production showed by the corresponding individual ingredients (Table 13).
- the other compositions 2-44 (C-2 to C-44) comprising G.
- glabra extract containing zinc salt of glycyrrhizin or potassium salt of glycyrrhizin or zinc/potassium double salt of glycyrrhizin and one ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; also exhibited synergism when compared to the increase in IL-2 production shown by each of their corresponding individual ingredient concentrations as summarized in Tables 13-17.
- compositions (C1-C44) also showed greater inhibitions of LTB 4 than the corresponding individual ingredients.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 ⁇ g/mL concentration and T. cordifolia water extract (T.C-1) at 2.5 ⁇ g/mL concentration showed 18.49% and 4.61% inhibition of LTB 4 , respectively.
- composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 ⁇ g/mL showed a 31.98% inhibition of LTB 4 , which is significantly higher than the additive effect of 23.10% (18.49%+4.61%) calculated from the inhibition of LTB 4 showed by the corresponding individual ingredients (Table 18).
- the other compositions 2-44 (C-2 to C-44) also showed synergistic inhibition of LTB 4 , as summarized in Tables 18-22.
- compositions (C1-C44) also showed greater inhibition of Histamine release than the corresponding individual ingredients.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 ⁇ g/mL concentration and T. cordifolia water extract (T.C-1) at 2.5 ⁇ g/mL concentration showed 36.46% and 8.92% inhibition of Histamine release, respectively.
- composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 ⁇ g/mL showed a 62.29% inhibition of Histamine release, which is significantly higher than the additive effect of 45.41% (36.46%+8.92%) calculated from the inhibition of Histamine release shown by the corresponding individual ingredients (Table 23).
- the other compositions 2-44 (C-2 to C-44) also showed synergistic inhibition of Histamine release as summarized in Tables 23-27.
- compositions comprising a first ingredient Glycyrrhiza glabra extract containing metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; have the tendency to show synergism when the corresponding individual ingredients are combined.
- the inventors achieved two methods for the preparation of these compositions; (i) neutralization of Glycyrrhiza glabra extract with corresponding metal compound(s); (ii) purifying the extract through cation exchange resin and then conducting neutralization as summarized below in FIG. 2.
- a second method i.e., preparation of zinc/potassium double salt of glycyrrhizin
- Purified glycyrrhizic acid is obtained by passing the 50% aqueous ethanol extract of G. glabra root through a cation exchange resin column.
- Glycyrrhizic acid thus obtained is neutralized with a metal oxide such as zinc oxide followed by metal carbonate such as potassium carbonate or metal hydroxide such as potassium hydroxide or mixtures thereof to yield zinc/potassium double salt of glycyrrhizin (Gly-3).
- the process for the preparation of synergistic compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof: and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; wherein the process comprises the following steps of,
- the suitable solvent used in the process for the preparation of the extracts or fractions or phytochemicals or mixtures thereof is selected from; C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol; ketones selected from acetone, methylisobutyl ketone; chlorinated solvents selected from methylene dichloride and chloroform; water and mixtures thereof, C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
- the metal used in the process for the preparation of the compositions is selected from zinc and potassium, and the metal compound used for the preparation of these compositions is in the form of their metal salts, metal oxides, metal hydroxides, or carbonates.
- the cation exchange resin used in the process for the preparation of the compositions is selected from strong and weak cation exchange resins, which include but not limited to Tulson T 42, Tulson CXO 12, Dowex marathon, Indion 225, Indion 236, Indion 730, Indion 652, Diaion SK1B, Diaion PK216, C 100, C 104, C 107, C 800 LT, C 800 MP, C 145, CG 10, D 001, Amberlite IRC 86, WK 11, WK 40L, D113.
- strong and weak cation exchange resins which include but not limited to Tulson T 42, Tulson CXO 12, Dowex marathon, Indion 225, Indion 236, Indion 730, Indion 652, Diaion SK1B, Diaion PK216, C 100, C 104, C 107, C 800 LT, C 800 MP, C 145, CG 10, D 001, Amberlite IRC 86, WK 11, WK 40L, D113.
- the present invention also provides synergistic herbal compositions comprising; the first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin, and mixtures thereof, and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally with at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- the synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; wherein the composition may be formulated with at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung
- compositions for airway allergic inflammation and immune modulation in ovalbumin-induced C57BL/6 mice:
- the compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; were evaluated for modulation of inflammation and immune response in ovalbumin-induced mice.
- Allergic airway inflammation is a serious global health concern affecting the mucosal tissue of the nasal cavity.
- the AAI is caused due to allergens, which are responsible for the induction of hypersensitivity reactions in the affected individuals.
- the allergens are any chemical or agent found indoor or outdoor, such as dust, mites, pollens, paints, molds, etc., to induce a cascade of inflammatory reactions mediated via the allergen-specific immunoglobulins.
- Acute activation and infiltration of inflammatory cells which include neutrophils, lymphocytes, mast cells, eosinophils, into the bronchial fluid and in the lungs, are the most characteristic features in airway inflammation. These inflammatory cells, upon recruitment, lead to the production of various inflammatory mediators.
- Ovalbumin-induced allergic airway inflammation in mice is a well-established and widely studied experimental model to study airway inflammation and immunomodulation.
- OVA ovalbumin
- CD4+ T cells play a major role in the initiation and maintenance of T helper cell, type 2 (Th2)-like allergic airway inflammation, that is characterized by increased number of eosinophil count (eosinophilia).
- Th2 type 2
- CD4+ T-cells play an important role in cell-mediated immune protection.
- CD4+ T cells produce Th2 cytokines that enhance immunoglobulin E (IgE) production and eosinophil accumulation.
- IgE immunoglobulin E
- a treatment that modulates the humoral immune response to suppress IgE production may be useful in reducing allergic reactions in inflammatory immune diseases, including allergic airway inflammation and other microbial infections.
- OVA induction causes increased accumulation of inflammatory cells that include neutrophil (neutrophilia), eosinophil in the bronchiolar lavage fluid in animals.
- neutrophil neutrophil
- eosinophil neutrophil in the bronchiolar lavage fluid in animals.
- mast cells produce histamine. Histamine is a potent inflammatory mediator associated with allergic reactions, promoting vascular and tissue changes and promotes inflammatory cells migration.
- Mast cells also mediate systemic immunosuppression induced by platelet-activating factors via the histamine-dependent mechanism.
- IFN- ⁇ interferon-gamma
- T. cordifolia water extract T.C-1
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin Gly-2
- Comp-45 composition of the major biomarkers that modulate inflammation and immune responses
- mice supplemented with the inventive compositions showed synergistic improvements in the modulation of the biomarkers such as Total Leucocytes, Neutrophils, Lymphocytes, and Eosinophils; serum interferon-gamma (IFN- ⁇ ) and IgE; inflammatory cells and mast cells; and CD4+ T-cell subset as summarized in Tables 28-32.
- the present compositions showed synergistic efficacy in decreasing Total Leucocytes, Neutrophils, Lymphocytes, and Eosinophils in the experimental animals.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 36.4% and 30.3% decreases in total Leucocytes respectively from OVA-induced mice.
- Comp-45 containing these two extracts at 2:1 ratio showed a 54.5% decrease from the OVA-induced mice, which is a significantly higher decrease than the corresponding individual ingredients, suggesting a synergistic effect between G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in decreasing total Leucocytes (Table 28).
- Gly-2 zinc/potassium double salt of glycyrrhizin
- T.C-1 T. cordifolia water extract
- comp-45 also showed significantly higher decreases than the corresponding individual ingredients in the number of Neutrophils, Lymphocytes, and Eosinophils, as summarized in Tables 28 & 29.
- the present compositions showed synergistic efficacies in modulating serum interferon-gamma (IFN- ⁇ ) and IgE in the experimental animals.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 17.6% and 14.0% increase in IFN- ⁇ respectively from OVA-induced mice.
- Comp-45 containing these two extracts at 2:1 ratio showed a 24.2% increase from the OVA-induced mice, which is a significantly higher increase than the corresponding individual ingredients, suggesting a synergistic effect between G.
- the present compositions showed synergistic efficacy in decreasing of inflammatory cells and mast cells in the lungs of experimental animals.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 38.7% and 29.0% decrease in total inflammation score (presence of peribroncheal+perivascular PMN cells), respectively from OVA-induced mice.
- Comp-45 containing these two extracts at 2:1 ratio showed a 51.6% decrease from the OVA-induced mice, which is a significantly higher decrease than the corresponding individual ingredients, suggesting a synergistic effect between G.
- Gly-2 zinc/potassium double salt of glycyrrhizin
- T.C-1 T. cordifolia water extract
- comp-45 also showed a significantly higher decrease in mast cells than the corresponding individual ingredients, as summarized in Table 31.
- the present compositions showed synergistic efficacy in increasing the CD4+ and CD8+ T-cell populations in the spleen of the experimental animals.
- G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 10.1% and 4.8% increase in CD4+ T-cell subset, respectively, from OVA-induced mice.
- Comp-45 containing these two extracts at 2:1 ratio showed a 17.6% increase from the OVA-induced mice, which is a significantly higher increase than the corresponding individual ingredients, suggesting a synergistic effect between G.
- compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; unexpectedly showed better efficacy in increasing the production of IFN- ⁇ and IL-2, and inhibition of LTB 4 and histamine release; when compared to their corresponding individual ingredients.
- the said compositions can be useful for ameliorating immunity, lung function, and respiratory health.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthen natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, run
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing zinc salt of glycyrrhizin; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for improving immunity, respiratory health that include allergic airway inflammation, cold and cough.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing potassium salt of glycyrrhizin; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for improving immunity, respiratory health that include allergic airway inflammation, cold and cough.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; for improving immunity, respiratory health that include allergic airway inflammation, cold and cough.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; wherein glycyrrhizin can be in the range of 2.0-50% and zinc can be in the range of 0.1-5.0% and potassium can be in the range of 0.1-10.0%.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; wherein the concentration of Glycyrrhiza glabra extract containing metal salt in the composition varies in the range of 10%-90% by weight and the concentration of the extract of Tinospora cordifolia or Zingiber officinale or Justicia adhatoda or Ocimum sanctum ; in the composition varies in the range of 90%-10% by weight.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; wherein the extracts or fractions or phytochemicals or mixtures thereof are obtained from at least one plant part selected from the group comprising leaves, stems, tender stems, tender twigs, aerial parts, whole fruit, fruit peel rind, seeds, flower heads, root, bark, hardwood, rhizome or whole plant or mixtures thereof.
- the present invention provides synergistic herbal compositions as disclosed above; wherein the extract, fraction, phytochemical or mixtures thereof, are produced using at least one solvent selected from C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol; ketones selected from acetone, methylisobutyl ketone, chlorinated solvents selected from methylene dichloride and chloroform; water and mixtures thereof; C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
- C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol
- ketones selected from acetone, methylisobutyl ketone
- chlorinated solvents selected from methylene dichloride and chloroform
- water and mixtures thereof water and mixtures thereof
- C1-C7 hydrocarbons such as hexane
- the present invention provides synergistic herbal compositions as described above; wherein the extract, fraction or mixtures thereof, in the composition are standardized to at least one phytochemical reference marker compound or pharmacologically active marker; wherein phytochemical marker compound or group of phytochemical compounds is in the concentration range of 0.01% to 90% by weight of the extract.
- the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin, and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- the present invention provides method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing the said human with an effective dose of a composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale
- the present invention provides the use of a synergistic herbal composition
- a synergistic herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthen
- composition as disclosed above is formulated into a dosage form selected from dry powder form, liquid form, beverage, food product, dietary supplement, or any suitable form such as a tablet, a capsule, a soft chewable tablet or gummy bear.
- the composition as disclosed above can be formulated into nutritional/dietary supplements that can be contemplated/made into the dosage form of healthy foods, or food for specified health uses such as solid food like chocolate or nutritional bars, semisolid food like cream, jam, or gel or beverage such as refreshing beverage, lactic acid bacteria beverage, drop, candy, chewing gum, gummy candy, yoghurt, ice cream, pudding, soft adzuki bean jelly, jelly, cookie, tea, soft drink, juice, milk, coffee, cereal, snack bar and the like.
- nutritional/dietary supplements such as solid food like chocolate or nutritional bars, semisolid food like cream, jam, or gel or beverage such as refreshing beverage, lactic acid bacteria beverage, drop, candy, chewing gum, gummy candy, yoghurt, ice cream, pudding, soft adzuki bean jelly, jelly, cookie, tea, soft drink, juice, milk, coffee, cereal, snack bar and the like.
- composition as disclosed above can be formulated into controlled-release tablets, using controlled release polymer-based coatings by the techniques including nanotechnology, microencapsulation, colloidal carrier systems and other drug delivery systems for obtaining the desired therapeutic benefit.
- Example 1 Glycyrrhiza glabra Extract Containing Zinc and Potassium Double Salt of Glycyrrhizin Method-1 (Gly-2)
- Method-2 The 50% aq ethanol extract prepared from 50 g of G. glabra dried root powder as described in method 1 was passed through a strong cation exchange resin (T-42H + ) column. The column was further eluted with 50% aqueous ethanol (400 mL). The acidic fractions were collected and mixed to give the total eluent. To the total eluent was added potassium carbonate (610 mg), zinc oxide (270 mg), potassium carbonate (300 mg), and potassium hydroxide (120 mg) in succession at 1 h intervals. The mixture was stirred at ambient temperature for 1 h, filtered, and the filtrate was evaporated under reduced pressure to give the product as a pale brown color solid (13.0 g).
- T-42H + strong cation exchange resin
- Example 1A Glycyrrhiza glabra Extract (Gly-1)
- G. glabra extract was prepared using the following procedure: G. glabra dried root powder (50 g) was extracted with 50% aqueous ethanol as described in example 1, and evaporation of the extract gave the product as a brown color solid (13.5 g).
- Example 2 Glycyrrhiza glabra Extract Containing Zinc Salt of Glycyrrhizin (Gly-4)
- G. glabra extract containing potassium salt was prepared from G. glabra dried root powder (50 g) as described in example 2 by replacing zinc oxide with potassium carbonate (915 mg) or potassium hydroxide or mixtures thereof, to give the product as a pale brown color solid (13.4 g).
- the G. glabra extracts containing metal salts disclosed above were analyzed for glycyrrhizic acid by analytical HPLC.
- the concentration of metals such as zinc, and potassium were analyzed by ICP-MS, and the results are summarized in Table 3.
- Example 5 Tinospora Cordifolia Water Extract (T.C-1)
- Example 6 Tinospora Cordifolia 50% Aqueous Ethanol Extract (T.C-2)
- Aqueous ethanol extract of T. cordifolia (100 g) was prepared as described in example 5 by replacing water with 50% aq ethanol to give the product as a brown color solid (8.3 g).
- Example 7 Tinospora Cordifolia Ethanol Extract (T.C-3)
- Ethanol extract of T. cordifolia (100 g) was prepared as described in example 5 by replacing water with ethanol to give the product as a brown color solid (2.1 g).
- the dried rhizome powder of Z. officinale was extracted using prior art procedures to give Z. officinale oleoresin.
- the extract was analyzed for total gingerols, and shogaols by HPLC method of analysis and found that the extract contains 30% of total gingerols and shogaols.
- Example 10 Zingiber officinale Oleoresin-2 (Z.O-2)
- Z. officinale oleoresin obtained above is further formulated using excipients such as zinc glycinate, xantham gum, Ultrasperse-A, magnesium hydroxide, MCC and syloid in a suitable solvent to get the product, which contains 5% of total zingerols and shogaols.
- excipients such as zinc glycinate, xantham gum, Ultrasperse-A, magnesium hydroxide, MCC and syloid in a suitable solvent to get the product, which contains 5% of total zingerols and shogaols.
- Example 11 Zingiber officinale 90% Aq Ethanol Extract (Z.O-3)
- Ethanol extract of J. adhatoda (100 g) was prepared as described in example 13 by replacing 70% aq methanol with ethanol to give the product as a brown color solid (5.6 g).
- the dried aerial parts powder of J. adhatoda (100 g) was extracted with 70% aqueous methanol as described in example 13.
- the product was further enriched by acidifying with 3% aqueous citric acid solution (700 mL) and washed with chloroform to remove impurities.
- the acidic solution was basified with ammonia solution, and the solution was extracted with chloroform.
- the organic layer was evaporated to give the alkaloid fraction (1.2 g), which contains majorly vasicine.
- Example 17 Ocimum sanctum 70% Aq Methanol Extract (O.S-1)
- Example 18 Ocimum sanctum 90% aq ethanol extract (O.S-2)
- Example 20 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Zinc/Potassium Double Salt of Glycyrrhizin (Gly-2) and Tinospora cordifolia Water Extract (T.C-1)
- composition-2A was prepared by combining G. glabra extract (Gly-1) and T. cordifolia water extract (T.C-1) in the ratio of 2:1.
- Example 21 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Zinc/Potassium Double Salt of Glycyrrhizin (Gly-2) and Zingiber officinale Oleoresin-2 (Z.O-2)
- composition-7A Composition for comparison (comp-7A):
- the composition-7A was prepared by combining G. glabra extract (Gly-1) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1.
- Example 22 Preparation of Various Compositions of G. glabra Extract Containing Zinc/Potassium Double Salt of Glycyrrhizin (Gly-2) and T. cordifolia 50% Aq Ethanol Extract (T.C-2)
- Example 23 Preparation of Various Compositions of G. glabra Extract Containing Zinc/Potassium Double Salt of Glycyrrhizin (Gly-2) and Z. officinale 90% Aq Ethanol Extract (Z.O-3)
- Example 24 Preparation of Various Compositions of G. glabra Extract Containing Zinc/Potassium Double Salt of Glycyrrhizin (Gly-2) and J. adhatoda 70% Aq Methanol Extract (J.A-1)
- Example 25 Preparation of Various Compositions of G. glabra Extract Containing Zinc/Potassium Double Salt of Glycyrrhizin (Gly-2) and O. sanctum 70% Aq Methanol Extract (O.S-1)
- Example 26 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Zinc Salt of Glycyrrhizin (Gly-4) and Tinospora cordifolia Water Extract (T.C-1)
- Example 27 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Zinc Salt of Glycyrrhizin (Gly-4) and Zingiber officinale Oleoresin-2 (Z.O-2)
- Example 28 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Zinc Salt of Glycyrrhizin (Gly-4) and Justicia adhatoda Enriched Extract (J.A-3)
- Example 29 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Zinc Salt of Glycyrrhizin (Gly-4) and Ocimum sanctum 90% Aq Ethanol Extract (O.S-2)
- Example 30 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Potassium Salt of Glycyrrhizin (Gly-5) and Tinospora cordifolia Ethanol Extract (T.C-3)
- Example 31 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Potassium Salt of Glycyrrhizin (Gly-5) and Zingiber officinale Oleoresin-1 (Z.O-1)
- Example 32 Preparation of Various Compositions of Glycyrrhiza glabra Extract Containing Potassium Salt of Glycyrrhizin (Gly-5) and Justicia adhatoda Ethanol Extract (J.A-2)
- Plasma Human blood was collected from healthy volunteers from a peripheral vein with a syringe containing EDTA at a final concentration of 2 mM. Plasma was separated by centrifugation at 150 ⁇ g for 10 min, and the residual blood was diluted with RPMI medium supplemented with 10% FBS and 2 mM EDTA at a ratio of 1:3. Thirty milliliters of blood were carefully layered onto 15 mL of Ficoll/Lymphoprep in a 50 mL falcon tube in the dark, and tubes were centrifuged at 350 ⁇ g for 30 min.
- PBMC peripheral blood mononuclear cells
- PBS cold 1 ⁇ phosphate-buffered saline
- Residual RBCs found in PBMCs pellet were removed by treating with ACK lysis buffer (Gibco, USA) and washed with fresh 1 ⁇ PBS.
- PBMC peripheral blood mononuclear cells
- ACK lysis buffer Gibco, USA
- the plate was centrifuged at 270 ⁇ g for 5 min to collect the cell-free culture supernatants. Quantitation of IL-2 was performed using the ELISA kit (R&D systems Cat #DY202) according to the manufacturer's instructions. Absorbance was measured at 450 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA). Percent increase in IL-2 production was calculated using the following formula.
- Example 36 Assay for Leukotriene B 4 (LTB 4 ) inhibition Human blood was collected from healthy volunteers from a peripheral vein with a syringe containing EDTA at a final concentration of 2 mM. Plasma was separated by centrifugation at 1000 rpm for 10 min, and the residual blood was diluted with RPMI medium supplemented with 10% FBS and 2 mM EDTA at a ratio of 1:3. Thirty milliliters of blood was carefully layered onto 15 mL of Ficoll/Lyymphoprep in a 50 mL falcon tube in the dark, and the tubes were centrifuged at 350 ⁇ g for 30 min.
- the settled RBC layer containing granulocytes was treated with ACK lysis buffer (Gibco Cat #A10492-01) to lyse the RBC completely. After centrifugation at 150 ⁇ g for 10 min, the resulting cell pellet of polymorphonuclear leukocytes (PMNs) was resuspended in RPMI containing 1% (v/v) newborn calf serum (NBCS). An equal number of PMNs (50,000 cells) was seeded in each well of a 96-well plate and treated with different concentrations of the test samples. Cells with 0.2% DMSO were served as vehicle control.
- ACK lysis buffer Gibco Cat #A10492-01
- the plate was incubated in a CO 2 incubator at 37° C. for 2 hrs. Finally, cells were induced with 10 ⁇ M A23187 (Sigma Chemical Co, USA) for 10 min, except the vehicle control cells. The plate was centrifuged at 150 ⁇ g for 5 min, and 120 ⁇ L of cell-free supernatants were collected. Quantitation of LTB 4 in the cell culture supernatants was performed using an LTB 4 ELISA kit (R&D Systems, USA) according to the manufacturer's instructions. Absorbance was measured at 450 nm with a correction wavelength of 570 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA). Percent reduction in LTB 4 production was calculated using the following formula.
- % ⁇ reduction ⁇ in ⁇ LTB 4 ( Conc . of ⁇ LTB 4 ⁇ in ⁇ Induction ) - ( Conc . of ⁇ LTB 4 ⁇ in ⁇ Test ⁇ Sample ) ( Conc . of ⁇ LTB 4 ⁇ in ⁇ Induction ) ⁇ 100
- RPCs Primary rat peritoneal cells
- cells were induced with 2.5 ⁇ M of A23187 (Sigma Chemical Co, USA) at 37° C. in a CO 2 incubator for 15 min. Cells with 0.2% DMSO served as vehicle control. The plate was centrifuged at 270 ⁇ g for 5 min to collect the cell-free culture supernatants. Twenty microliters of 1N NaOH were added to all wells of a 96-well black clear bottom plate. To this plate, 100 ⁇ l of the cell-free supernatants were added, followed by 5 ⁇ l of O-Phthalaldehyde (OPA), and incubated for 3 min on a shaker in the dark. The reaction was stopped with 10 ⁇ l of stop solution (3N HCl) and mixed the content thoroughly.
- OPA O-Phthalaldehyde
- Relative fluorescence was measured at Ex/Em: 360/440 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA) for estimating the spontaneous histamine release. Percent reduction of spontaneous histamine release from the primary peritoneal cells was calculated using the following formula.
- mice in G1 and G2 received Carboxymethylcellulose (CMC) as a vehicle, and G3-G5 received 100 mg per kg BW of T.C-1, Gly-2, and comp-45 mixed with CMC through oral gavage for 12 days.
- CMC Carboxymethylcellulose
- G3-G5 received 100 mg per kg BW of T.C-1, Gly-2, and comp-45 mixed with CMC through oral gavage for 12 days.
- each mice in G2-G5 was sensitized with 100 ⁇ g OVA in 200 ⁇ L alum adjuvant via the intraperitoneal route.
- These animals were given intranasal challenges with 100 ⁇ g OVA (in 50 ⁇ L sterile 1 ⁇ PBS) on day 8, and 50 ⁇ g OVA (in 50 L 1 ⁇ PBS) on days 10 and 12 under mild anesthesia.
- the G1 or vehicle control animals received equivalent volumes of sterile PBS on the days of OVA sensitization and challenges.
- Serum biomarker analysis IFN- ⁇ and IgE: The levels of IFN- ⁇ and IgE in the rat serum samples were analyzed using enzyme-linked immunosorbent assay (ELISA) kits. Briefly, 100 ⁇ L of respective samples/standards were added to respective wells of the pre-coated 96-well ELISA plates and incubated for 2.5 hours at room temperature. After the incubation, the plates were washed with 1 ⁇ wash buffer; 100 ⁇ L of 1 ⁇ prepared detection antibody was added and incubated for 1 hour at room temperature with gentle shaking. After washing the wells, 100 ⁇ L Streptavidin solution was added; the plate was sealed and incubated for 45 minutes at room temperature with gentle shaking.
- ELISA enzyme-linked immunosorbent assay
- TMB substrate was added; plates were sealed and incubated for 30 minutes in the dark at room temperature with gentle shaking. In each well, fifty microliters of stop solution were added, and absorbance was measured at 450 nm using a microplate reader (Spectramax2e, Molecular Devices, San Jose, CA). The levels of IFN- ⁇ and IgE were quantified utilizing the respective standard curves generated for the respective analyte.
- CD4 and CD8 cell population analysis in splenocytes The spleens of the experimental mice were gently crushed on Falcon® 100 ⁇ m sterile cell strainers (Corning, USA) using 1 ⁇ RPMI medium to obtain single cells suspension of splenocytes. The splenocytes were counted, and 0.3 ⁇ 10 6 splenocytes suspended in FACS buffer were taken into each well of a ‘v’ bottom 96-well plate and processed for flow cytometry staining.
- the cells were washed with FACS buffer and incubated 70 ng of PE anti-mouse CD4 Antibody (BioLegend, USA) and 70 ng of APC anti-mouse CD8a Antibody (BioLegend, USA) for 30 minutes in the dark at room temperature. After the incubation, the cells were washed with FACS buffer and fixed using 100 ⁇ L of BD CytofixTM Fixation Buffer (BD Biosciences, USA) for 20 minutes in the dark. After incubation, the cells were washed with FACS buffer and resuspended in the same buffer and acquired on BD FACSVerse flow cytometer for analysis. Percent positive CD4+ and CD8+ populations were recorded.
- the lung tissues were fixed in 0% neutral buffered formalin for 48 hours in the dark at room temperature.
- the fixed tissues were embedded in paraffin and the paraffin-embedded tissues were sectioned at 4-micron sizes in a rotary microtome.
- the tissue sections were stained with hematoxylin-eosin and toluidine blue to examine the inflammatory cells and mast cells, respectively.
- the stained tissue sections were examined under 10 ⁇ objective of a light microscope (Axio scope Al, Carl Zeiss, Germany). For each parameter, one hundred random fields were examined. The results are presented in Tables: 28-32.
- T.C-1 cordifolia water extract
- Comp-45 Lymphocytes Eosinophils Differential % Differential % count decrease count decrease (% of from (% of from Experimental total OVA- total OVA- group Leucocytes) induced Leucocytes) induced Vehicle control 3.8 — 0.3 — (G1) OVA-induced 5.6 — 5.5 — (G2) OVA + T.C-1 4.6 17.8 3.3 40.9 (G3) OVA + Gly-2 4.4 22.2 2.9 47.7 (G4) OVA + Comp-45 4.0 28.9 2.0 63.6 (G5)
- T.C-1 cordifolia water extract
- Comp-45 T cell subsets in spleen Mean Mean population % increase population % increase Experimental of CD4+ from OVA- of CD8+ from OVA- group cells (%) induced cells (%) induced Vehicle control 20.0 — 10.4 — (G1) OVA-induced 15.7 — 10.0 — (G2) OVA + T.C-1 16.4 4.8 10.1 0.9 (G3) OVA + Gly-2 17.2 10.1 10.3 3.4 (G4) OVA + Comp-45 18.4 17.6 10.7 7.6 (G5)
- compositions (C-1 to C-44) of the present invention unexpectedly showed synergistic efficacy in increasing the production of IFN- ⁇ (tables 8-12) and IL-2 (tables 13-17) and in inhibiting the production of LTB 4 (Tables 18-22); and in inhibiting Histamine release (tables 23-27) when compared to their corresponding individual ingredients.
- compositions (C-1 to C-44) of the present invention unexpectedly showed synergistic efficacy in decreasing the total Leucocytes and Neutrophils (table 28); decreasing in Lymphocytes and Eosinophil (table 29) count in bronchoalveolar lavage (BAL) fluid; increasing serum interferon-gamma (IFN- ⁇ ) production and decreasing serum IgE (table 30) in experimental mice when compared to individual ingredients. Furthermore, it is demonstrated by the present inventors that the compositions (C-1 to C-44) of the present invention decreases inflammatory cells and mast cells count in the lungs (table 31) and increases the count in CD4+ and CD8+ T-cell subsets (table 32) in the spleen of the experimental mice.
- the synergistic compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda , and Ocimum sanctum ; are useful for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose
Abstract
The present invention discloses synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; process for their preparation, methods of treatment and use of such compositions for improving immunity and improving respiratory health that include allergic airway inflammation, cold and cough.
Description
- The invention relates to synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for obtaining at least one health benefit selected from improving immunity and improving respiratory health that include allergic airway inflammation, cold and cough.
- Immunity: Immunity is the body's natural defense system against various bacterial/viral/fungal infections, diseases, and different environmental stimuli. Primarily, host immunity is classified into innate and adaptive immune responses. Innate immune responses are rapid and non-specific to pathogens, which are mediated by innate immune cells such as myeloid cells, natural killer (NK) cells, innate lymphoid cells, and humoral systems such as defensins and complement systems. Adaptive immune responses are slower but specific to the infections with the recruitment of B- and T-lymphocytes and generation of long-lived immunological memory. Recent research has demonstrated the strong coordinated network between the innate and adaptive immune systems to effectively tackle the infections through bidirectional activation through eliciting innate immune responses such as phagocytosis and B/T-cell-mediated adaptive immune responses. However, if these immune responses are excessively or inappropriately activated, autoimmune disorders like rheumatoid arthritis, allergies, and cancers may develop.
- Respiratory health: The lungs are constantly exposed to the external environment and come in contact with potential air-borne pathogens, allergens, and environmental pollutants. This constant exposure requires an effective and fast-acting immune system. Hence, the pulmonary immune system contains a broad armamentarium of cellular and humoral defense mechanisms in the airways. The coordinated and complex interplay between the resident airway epithelial cells and infiltrating immune cells along with the secretions of defensins, mucins, or collectins shape the outcome of host-pathogen, host-allergen, host-particle interactions within the airway microenvironment. These interactions further activate the downstream immune responses through the release of mediators such as chemokines (CCL-2, CCL-20), cytokines (IL-1α, IL-1β), and lipid mediators (eicosanoids/leukotrienes). Conversely, excessive immunological tolerance in the airways may lead to an ineffective clearance of infectious agents such as influenza, tuberculosis, respiratory syncytial virus, Streptococcus pneumoniae, or coronavirus, which may lead to inflammatory lung disease, bronchitis, pneumonia, and sepsis.
- Allergic airway inflammation: Airway inflammation, including asthma and allergic rhinitis, is the common chronic respiratory illness worldwide. Low temperature, accompanying low air humidity, air pollutants (such as pollen, dust, etc.) affect the respiratory epithelium and induce hyper responsiveness (bronchial allergy) and narrowing of the respiratory airways. Poor air quality and cold air also influence chronic airway inflammation, which is likely to aggravate respiratory symptoms. Epidemiological studies have shown that respiratory symptoms such as wheezing, cough, runny, stuffy nose, congestion, phlegm (a byproduct of inflammation in the sinuses and the lungs) are common among adults and children. A decline in lung function and a high prevalence of respiratory symptoms in the cold indoor environment have also been reported. Allergic airway inflammation is characterized by reversible airway obstruction, airway hyper-responsiveness (AHR), infiltration of eosinophils and type 2 T-cells (that activate eosinophils and mast cells) into the airway submucosa, mucus hypersecretion, and airway remodeling. In the hypersensitivity (allergic) reaction, the allergen-specific immunoglobulins of the IgE class bound to the surfaces of basophils and mast cells present in the sub-epithelial layer of the airways. These bound IgE molecules immediately release leukotrienes, prostaglandins, and histamine. These mediators contract airway smooth muscle cells and induce edema and mucus secretion, leading to narrowed, constricted airways. Locally produced chemokines stimulate the recruitment of eosinophils, macrophages, neutrophils, and T-lymphocytes in the airways.
- Common cold: Common cold (synonyms: acute coryza, acute viral nasopharyngitis) is a highly contagious viral disease of the upper respiratory tract involving the nose, sinuses, pharynx, and larynx. At least 200 identified viruses are capable of causing the common cold. Among these, rhinoviruses, coronaviruses, parainfluenza viruses, respiratory syncytial virus, adenoviruses, and enteroviruses are common. The histologic effects of infection vary from mild to severe epithelial destruction. The infection causes vasodilation and hypersecretion. The common clinical symptoms include nasal congestion, nasal discharge, postnasal drip (PND), throat clearing, sneezing, and cough.
- Cough: Cough is a forced expulsive maneuver, usually against a closed glottis and which is associated with a characteristic sound. An acute cough is defined as one lasting less than 3 weeks. It is the commonest symptom associated with acute exacerbations and hospitalizations with asthma and chronic obstructive pulmonary disease (COPD). Chronic cough is defined as one lasting more than 8 weeks. Most patients present with a dry or minimally productive cough. Because of the variable and episodic nature of acute cough, cough suppressants such as dextromethorphan, menthol, sedative antihistamines, codeine or pholcodine are used.
- Current synthetic drugs hold no promise in the complete healing of these disorders and also they have some safety concerns. Thus there is a scope for the provision of safe and potent herbal formulations having built-in immune-stimulating and inflammation-modulating effects to viral respiratory infections while still helping the immune system cope better with the infections.
- Patent publication U.S. Pat. No. 6,979,471B1 disclosed a composition comprising a bio-enhancer or bioavailability facilitator selected from the group consisting of isolated and purified glycyrrhizic acid, isolated and purified glycyrrhizin or mixtures thereof in a concentration of about 1 μg/ml and an agent selected from one or more nutraceuticals, antibiotics, anti-infective agents, and anti-cancer agents.
- Another patent publication US20030228383A1 disclosed a herbal composition for the treatment of chronic respiratory disorders such as cold, cough, allergic asthma, seasonal allergic rhinitis, pharyngitis, laryngitis comprises extracts derived from Ayurvedic plants selected from the Ocimum sanctum, Glycyrrhiza glabra, Curcuma longa, Zingiber officinale, Adhatoda vasika, Solanum indicum, Saussurea lappa, Piper cubeba, Terminalia bellirica, Aloe barbadensis, Inula racemosa, Clerodendrum serratum, Solanum xanthocorpum, Pipper longum, Alpinia galangal, Terminalia chebula, Emblica officinalis and a process for preparing the same.
- Another patent publication EP1529445B1 disclosed a dietary supplement composition comprising an active ingredient, a vegetable protein containing carrier, a vegetable source for sugar, a vegetable source for fat, and salt, wherein the active ingredient is constituted by a mixture of 14-26% of Zingiber officinalis, 14-26% of Piper longum, 14-26% of Piper nigrum, 14-26% of Cucumis trigonus, and 14-26% of Glycyrrhiza glabra.
- Patent publications CN1010373B, CN104530177B, CN105541956A and CN1120172C disclosed various process techniques for the preparation of licorzinc (zinc glycyrrhizinate) from glycyrrhizic acid.
- To the best of inventor's knowledge, synergistic herbal compositions comprising a first ingredient zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra; and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum are not known in the literature.
- So there is a continuous need in the art to provide potent natural Glycyrrhiza glabra extract salts and their compositions for boosting immune function, rejuvenating the immune system, regulating the immune system, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with cold, cough, flu, runny nose and sinus symptoms.
- Therefore, the main object of the present invention is to provide synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
- Another objective of the invention is to provide method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing the said human with an effective dose of a composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- Yet another objective of the invention is to provide the use of a synergistic herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
- The present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
- Another aspect of the invention provides synergistic herbal compositions comprising a first ingredient, Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- In a further aspect, the invention provides a process for the preparation of the compositions comprising a first ingredient, Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- In yet another aspect, the invention provides method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing the said human with an effective dose of a composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- In a further aspect, the invention provides the use of a synergistic herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
- The invention will now be described in detail in connection with certain preferred and optional embodiments so that various aspects thereof may be more fully understood and appreciated.
- The terms glycyrrhizin and glycyrrhizic acid are the same and are interchangeable. Thus the statements “zinc/potassium double salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizic acid and zinc/potassium double salt of glycyrrhizinate” made in the specification convey the same meaning and are interchangeable. Similarly, zinc salt of glycyrrhizin, zinc salt of glycyrrhizic acid and zinc salt of glycyrrhizinate; potassium salt of glycyrrhizin, potassium salt of glycyrrhizic acid and potassium salt of glycyrrhizinate; also conveys the same meaning and are used interchangeably in the specification.
- The terms “improve”, “ameliorate,” and “better” as used herein, conveys the same meaning and are interchangeable. Unless stated to the contrary, any of the words, “including”, “includes”, “comprising”, and comprises” mean “including without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items. The terms “metal salt”, “metal complex” and “metal chelate” also convey the same meaning and are used interchangeably in the specification. Unless specified otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- The source of the herbs used in the invention is as follows:
-
- 1. Glycyrrhiza glabra was procured from the local market.
- 2. Justicia adhatoda was collected from Hanumanthulagudem village, Hanumanthulagudem Panchayati, Nuzividu Mandal, Krishna District, Andhra Pradesh and it was wild.
- 3. Zingiber officinale was collected from Penubaka village, Penubaka Panchayati, Tadepalli Mandal, Guntur District, Andhra Pradesh, and it was cultivated.
- 4. Tinospora cordifolia was collected from Mulapadu village, Mulapadu Panchayati, Ibrahimpatnam Mandal, Krishna District, Andhra Pradesh, and it was wild.
- 5. Ocimum sanctum was collected from Kondapalli village, Ibrahimpatnam Panchayati, Ibrahimpatnam Mandal, Krishna District, Andhra Pradesh, and it was wild.
- Glycyrrhiza glabra: G. glabra is a widely used and extensively researched medicinal plant around the world. In Ayurveda, it is used for treating coughs, colds, and chills. In traditional medicine, its roots have been used for treating chest and lung diseases, pneumonia, bronchitis, arthritis, bronchial asthma, kidney diseases, heart diseases, gastric ulcer, mouth ulcers, coughs, swellings, excessive salivation, fluid retention, low blood pressure, allergies, catarrhs of the upper respiratory tract, liver toxicity, hyperglycemia, and certain viral infections. Glycyrrhiza glabra contains several phytochemical constituents and out of which glycyrrhizin (glycyrrhizic acid) is the major active phytochemical.
- Glycyrrhizin: Glycyrrhizin, also called as glycyrrhizic acid, is a triterpenoid saponin obtained from the root and rhizome extracts of Glycyrrhiza glabra (Licorice). Glycyrrhizic acid is the major characteristic constituent of licorice, which is primarily responsible for its pharmacological activities and sweet taste. It is widely used in traditional Indian, Chinese, and Tibetan medicinal preparations. Glycyrrhizic acid is also used as a sweetener in many applications, and it is reported to be 30-50 times sweeter than sucrose. Pharmacologically, glycyrrhizin is used as an anti-inflammatory, anti-thrombin, anti-tumor, anti-ulcer, anti-allergic, anti-oxidant, anti-viral agent, and also for treating chronic hepatic diseases. The chemical structure of glycyrrhizin is shown below (FIG. 1).
- Zinc is the second most abundantly distributed trace element in the body after iron. It is found only in modest amounts in varieties of food, such as beef, poultry, seafood, and grains. It is needed for wound healing, sense of taste and smell, DNA synthesis, and it supports normal growth and development during pregnancy, childhood, and adolescence. Zinc deficiency in the body can lead to a variety of health-related problems. Zinc is essential for the biological activity of over 300 enzymes that aid in metabolism, digestion, nerve function, and many other processes. Zn is known to be important in immune function, DNA and protein production, and cell division.
- Potassium is the essential mineral needed in higher quantity than any other metal, with a requirement of up to 3500 mg per day. Potassium plays a vital role in blood pressure regulation, carbohydrate metabolism, and fluid balance. The functions of potassium and sodium in living organisms are quite different. Potassium is the major cation present inside the animal cells, while sodium is the major cation present outside the animal cells, and they play a critical role in maintaining membrane potential. As sodium consumption rises, increased potassium is needed to balance the effect of sodium on blood pressure.
- The inventors surprisingly found that the zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra is useful to improve immunity, lung function, respiratory health, and treating/alleviating symptoms associated with cold and cough. Zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra is not known in the literature.
- Therefore, the present invention provides synergistic herbal compositions comprising a first ingredient zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra; and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda and Ocimum sanctum; further containing optionally at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- After several experimental trails, the inventors achieved the preparation of zinc/potassium double salt of glycyrrhizin derived from Glycyrrhiza glabra; by two methods, (i) neutralization of G. glabra extract with zinc oxide and potassium carbonate; and (ii) G. glabra extract was purified by cation exchange resin and the glycyrrhizin thus obtained was neutralized with zinc oxide and potassium carbonate.
- Thus, the 50% aqueous ethanol extract of Glycyrrhiza glabra was neutralized with metal oxide such as zinc oxide followed by metal carbonate such as potassium carbonate or metal hydroxide such as potassium hydroxide or mixtures thereof to yield zinc/potassium double salt of glycyrrhizin (Gly-2). The extract was analyzed for glycyrrhizin by the HPLC method of analysis and found that the extract contains 14.88% of glycyrrhizin. Zinc and potassium were estimated by ICP mass and found that the extract contains 0.9% of zinc and 2.5% of potassium (Example 1).
- In the second method, purified glycyrrhizic acid was obtained by purification of 50% aqueous ethanol extract of Glycyrrhiza glabra root through a cation exchange resin column. The glycyrrhizic acid thus obtained was neutralized with metal oxide followed by metal carbonate or metal hydroxide or mixtures thereof to yield zinc/potassium double salt of glycyrrhizin (Gly-3).
- Similarly, zinc salt of glycyrrhizin derived from G. glabra (Gly-4); and potassium salt of glycyrrhizin derived from G. glabra (Gly-5) were also prepared. For comparison, 50% aqueous ethanol extract of G. glabra was also prepared (Gly-1). These extracts were analyzed for glycyrrhizin by HPLC. Zinc and potassium by ICP mass and the results are summarized in Table-3.
- Salt formation: The chemical structure of glycyrrhizic acid contains three carboxylic acid groups, which are capable of forming salts with bases. Glycyrrhiza glabra extract containing glycyrrhizic acid when treated with metal oxides, metal hydroxides, and metal carbonates etc., forms metal salt of glycyrrhizic acid. For example, neutralization of Glycyrrhiza glabra extract with zinc oxide and potassium carbonate followed by filtration of the solution to remove water insoluble and unreacted zinc oxide gave Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizic acid. The presence of zinc and potassium by ICP-MS analysis of the extract clearly indicates the formation of salt.
- To address the problem and to provide safe herbal composition(s) for improving immunity, respiratory health that include allergic airway inflammation, cold, and cough, the following cell-based assays have been conducted to evaluate the efficacy of the compositions in boosting immune function, respiratory health that include allergic airway inflammation, cold, and cough.
-
- (i) Interferon-γ (IFN-γ) production
- (ii) Interleukin-2 (IL-2) production
- (iii) Leukotriene B4 (LTB4) inhibition
- (iv) Histamine assay
- Interferon-γ: INF-γ is a cytokine produced mainly by Th1 lymphocytes in response to microbes, intracellular parasites, viruses, and autoimmune reactions. Interferon-γ (IFN-γ) has been shown to have profound effects on both innate and adaptive immunity, which contribute to host protection. IFN-γ is produced by adaptive CD4+ Th1 T cells, CD8+ cytotoxic T cells, natural killer (NK) cells, B cells, NKT cells, and innate professional antigen-presenting cells (APCs) [monocyte/macrophage, dendritic cells (DC)]. IFN-γ has a critical role in recognizing and eliminating pathogens as it can coordinate a plethora of anti-microbial and anti-viral functions through cell-mediated immunity. It can enhance the antigen recognizing capacity of APCs and amplify their antigen presentation to the T cells, subsequently increasing the production of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNIs) and induce anti-viral responses. In the context of viral infections, INF-γ treatment protects neurons from varicella-zoster virus and limit Hepatitis C virus proliferation in HIV patients. In this regard, compounds promoting INF-γ production would be important to boost the host immune system and also for improving respiratory health.
- Interleukin-2: Interleukin-2 (IL-2) was one of the first cytokines discovered. It can promote T cell proliferation and differentiation in vitro and plays a crucial role during antigen-driven clonal expansion of T cells in vivo. With respect to immune activation in vivo, IL-2 has a role in the proliferation and survival of T cells and differentiation of T cells into effector T cells. In the case of chronic infection, IL-2 is also an important factor in generating memory T cells that can undergo secondary expansion when they re-encounter the antigen. Alternatively, IL-2 can promote activation-induced cell death (AICD) of the T cells, down-regulating the immune response after the clonal expansion of antigen-specific T cells. IL-2 can also prime CD8+ T cells with non-infectious immunogens. Conversely, very high levels of IL-2 can bind to CD25 and differentiate the T cells into regulatory T cells (Tregs), which will suppress the excessive immune response. In this regard, compounds promoting IL-2 production would be important to boost the host immune system.
- Leukotriene B4 (LTB4): Leukotriene B4 is a metabolite of the 5-lipoxygenase pathway and was discovered in 1979. The leukotrienes (LTs), a family of proinflammatory lipid mediators, play an important role in the pathogenesis of allergic inflammation and are divided into two classes: the chemoattractant LTB4 and the spasmogenic cysteinyl LTs [CysLTs: LTC4, LTD4, and LTE4]. LTB4 cannot be stored and released, but it is synthesized from arachidonic acid in activated innate immune cells such as granulocytes, macrophages, and mast cells following several enzymatic steps. Three distinct receptors for LTB4 are PPARα, BLT1, and BLT2. LTB4 is closely related to the pathogenesis of several allergic diseases, including allergic rhinitis. Allergen-induced nasal congestion and increased LTB4 levels in nasal lavage fluid of patients with allergic rhinitis were significantly decreased by treatment with LTB4 antagonists. Leukotrienes are potent inflammatory mediators of chemotaxis, bronchoconstriction, and vascular permeation, which are predominately produced by leucocytes but also by other inflammatory immune cells and in cough-associated eosinophilic inflammation, blockade of leukotriene receptors has been shown to be efficacious in cold and cough treatment.
- Histamine: Histamine is an active substance that plays a major role in an allergic reaction, dilating blood vessels and increasing the permeability of vessel walls. It exerts its effects by binding to histamine receptors (H1, H2, H3, and H4) on cells' surfaces. The H1 histamine receptor plays an important role in allergic response and is widely distributed in smooth muscle, where its activation causes vasoconstriction. Activation of the H1 receptor also causes blood vessel dilation, increased vessel permeability, stimulation of sensory nerves in the airways, and bronchoconstriction. In addition, activation of this receptor promotes the chemotaxis of eosinophils, which can lead to nasal congestion, sneezing, and rhinorrhea. Hence Antihistamines are effectively used for the treatment of some allergic disorders, which act by competing with histamine released from mast cells in mucous membranes for receptor sites in target organs. Upper respiratory tract disorders are the most common causes of chronic and acute cough in humans. It has recently been proposed that the host of upper respiratory disorders that frequently cause cough to be collectively described as upper airway cough syndrome (UACS). A possible mechanism by which antihistamines could inhibit pathologic cough is by binding to nonhistaminergic receptors in the central nervous system that control cough excitability which could further regulate nasal mucus secretion.
- Hence, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2), G. glabra extract containing zinc salt of glycyrrhizin (Gly-4) and G. glabra extract containing potassium salt of glycyrrhizin (Gly-5); were screened for their IFNγ and IL-2 production in comparison with regular G. glabra extract (Gly-1). Interestingly, G. glabra extract containing salts potently elevated the levels of said cytokines; and showed greater improvements in the production of IFN-γ and IL-2 compared to the regular G. glabra extract.
- For example, IFNγ production activity of G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) showed an 18.18% increase in IFNγ production at 10 μg/mL, whereas G. glabra regular extract (Gly-1) showed a 13.86% increase in IFNγ production at 10 μg/mL. This is a surprising and unexpected result for enhancement of IFNγ production activity of the G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) compared to the corresponding G. glabra direct extract (Gly-1; Table-1). Similarly, G. glabra extract containing zinc salt of glycyrrhizin (Gly-4) and G. glabra extract containing potassium salt of glycyrrhizin (Gly-5) also showed higher efficacy in IFNγ production activity than the G. glabra direct extract (Gly-1).
-
TABLE 1 Percent increase of IFNγ and IL-2 production of the G. glabra extract containing metal salt of glycyrrhizin and direct extract (Gly-1) % Increase % Increase of IFN-γ of IL-2 Example production at production at # Product Description 10 μg/mL 10 μg/mL 1A G. glabra regular extract 13.86 7.96 (Gly-1) 1 G. glabra extract containing 18.18 12.93 zinc/potassium double salt of glycyrrhizin (Gly-2) 2 G. glabra extract containing 17.2 10.22 zinc salt of glycyrrhizin (Gly-4) 3 G. glabra extract containing 17.49 10.70 potassium salt of glycyrrhizin (Gly-5) - Similarly, IL-2 production assay of G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) showed a 12.93% increase in IL-2 production at 10 μg/mL, whereas G. glabra regular extract (Gly-1) showed a 7.96% increase in IL-2 production at 10 μg/mL. This is also a surprising and unexpected improvement in IL-2 production activity of the G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2, Table 1). Similarly, other salts also showed higher efficacy in IL-2 production activity than the G. glabra regular extract (Gly-1).
- Thus the present invention provides improved Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin; wherein Glycyrrhiza glabra extract comprises glycyrrhizin in the range of 2.0-50%, zinc in the range of 0.1-5.0% and potassium in the range of 0.1-10.0%.
- Encouraged by the increased efficacy of Glycyrrhiza glabra extract containing metal salts of glycyrrhizin in increasing production of IFN-7 and TL-2 levels, the inventors have prepared compositions comprising Glycyrrhiza glabra extract containing metal salts of glycyrrhizin in combination with at least one ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; to explore the efficacy of these compositions in improving immunity and respiratory health.
- Thus, various solvent extracts of Tinospora cordifolia or Zingiber officinale or Justicia adhatoda, or Ocimum sanctum; were prepared. T. cordifolia dried stem was pulverized, and the powder was extracted with water, and the extract was concentrated to obtain water extract (T.C-1). Similarly, T. cordifolia dried stem powder was extracted with other solvents such as 50% aq ethanol and ethanol to obtain 50% aq ethanol extract (T.C-2) and ethanol extract (T.C-3), respectively. These extracts of T. cordifolia were standardized to 8-hydroxytinosporide by the analytical HPLC method of analysis, and the results are summarized in Table 4.
- Similarly, various solvent extracts of Zingiber officinale were prepared as shown in examples 9-11, and these extracts were standardized to total gingerols and shogaols as summarized in Table 5. Similarly, various solvent extracts of Justicia adhatoda and Ocimum sanctum were also prepared, as shown in examples 13-19, and these extracts were standardized to vasicine and total of oleanolic acid and ursolic acid, respectively, as summarized in Tables 6 & 7.
- The inventors then prepared four compositions; (a) composition-2 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in the ratio of 2:1; (b) composition-2A comprising G. glabra extract (Gly-1) and T. cordifolia water extract (T.C-1) in the ratio of 2:1, a comparative composition without salt; (c) composition-7 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1; and (d) composition-7A comprising G. glabra regular extract (Gly-1) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1, a comparative composition without salt. These four compositions are tested for their efficacy in increasing the production of IFN-7 and L-2 in in-vitro cellular models, and the results are summarized in Table 2.
-
TABLE 2 Efficacy of compositions comprising Glycyrrhiza glabra extract containing zinc/potassium salt of glycyrrhizin or regular extract and Tinospora cordifolia water extract or Zingiber officinale oleoresin-2 % Increase in % Increase in IFN-γ IL-2 Comp production at production at # Composition Description 10 μg/mL 10 μg/mL Comp- G. glabra extract (Gly-1) and 16.81 10.63 2A T. cordifolia water extract (T.C-1) in the ratio of 2:1 Comp- G. glabra extract containing 23.18 15.96 2 zinc/potassium salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C- 1) in the ratio of 2:1 Comp- G. glabra extract (Gly-1) and 18.23 9.94 7A Z. officinale oleoresin-2 (Z.O- 2) in the ratio of 3:1 Comp- G. glabra extract containing 22.87 15.86 7 zinc/potassium salt of glycyrrhizin (Gly-2) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1 - From the above table, IFN-γ production of the composition-2 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in the ratio of 2:1 showed 23.18% increase at 10 μg/mL. While similar composition with regular G. glabra extract without salt (comp-2A) showed a 16.81% increase in IFN-γ production at 10 μg/mL, this is a surprising and unexpected result for enhancement of IFN-γ production activity of the composition-2 compared to the corresponding comparative composition without salt (Table 2). Similarly, IL-2 production of the composition-2 showed a 15.96% increase at 10 μg/mL, whereas the similar composition without salt (comp-2A) showed a 10.63% increase in IL-2 production at 10 μg/mL. This is also a surprising and unexpected improvement. Similarly, composition-7 comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1 also showed surprisingly higher efficacy in improving IFN-γ and IL-2 production than the composition without salt (comp-7A). Hence, the compositions comprising G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) with other herbal extracts such as T. cordifolia or Z. officinale showed better efficacy in increasing production of IFN-γ and IL-2 when compared to the corresponding compositions without salt.
- Following this surprise result, various compositions of Glycyrrhiza glabra extract containing metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin; in combination with at least one extract derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; were prepared as summarized in examples 20-32.
- Then, these compositions (C1-C44) were tested for their efficacy in increasing the production of IFN-γ, IL-2, and inhibition of LTB4, Histamine release in in-vitro cellular models compared to the corresponding individual ingredients. Unexpectedly, these compositions showed synergistic activity.
- For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 μg/mL concentration and Tinospora cordifolia water extract (T.C-1) at 2.5 μg/mL concentration showed 13.64% and 3.01% increase in IFN-γ production, respectively. The composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 μg/mL showed a 23.49% increase in IFN-γ production, which is significantly higher than the additive effect of 16.65% (13.64%+3.01%) calculated from the increase in IFN-γ production showed by the corresponding individual ingredients (Table 8). The other compositions 2-44 (C-2 to C-44) comprising G. glabra extract containing zinc salt of glycyrrhizin or potassium salt of glycyrrhizin or zinc/potassium double salt of glycyrrhizin and one ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; also exhibited synergism when compared to the increase in IFN-γ production shown by each of their corresponding individual ingredient concentrations as summarized in Tables 8-12.
- Further, the compositions (C1-C44) also showed greater increases in IL-2 production than the corresponding individual ingredients. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 μg/mL concentration and T. cordifolia water extract (T.C-1) at 2.5 μg/mL concentration showed 9.70% and 2.43% increase in IL-2 production, respectively. The composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 μg/mL showed a 16.23% increase in IL-2 production, which is significantly higher than the additive effect of 12.13% (9.70%+2.43%) calculated from the increase in IL-2 production showed by the corresponding individual ingredients (Table 13). The other compositions 2-44 (C-2 to C-44) comprising G. glabra extract containing zinc salt of glycyrrhizin or potassium salt of glycyrrhizin or zinc/potassium double salt of glycyrrhizin and one ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; also exhibited synergism when compared to the increase in IL-2 production shown by each of their corresponding individual ingredient concentrations as summarized in Tables 13-17.
- Further, the compositions (C1-C44) also showed greater inhibitions of LTB4 than the corresponding individual ingredients. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 μg/mL concentration and T. cordifolia water extract (T.C-1) at 2.5 μg/mL concentration showed 18.49% and 4.61% inhibition of LTB4, respectively. The composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 μg/mL showed a 31.98% inhibition of LTB4, which is significantly higher than the additive effect of 23.10% (18.49%+4.61%) calculated from the inhibition of LTB4 showed by the corresponding individual ingredients (Table 18). The other compositions 2-44 (C-2 to C-44) also showed synergistic inhibition of LTB4, as summarized in Tables 18-22.
- Further, the compositions (C1-C44) also showed greater inhibition of Histamine release than the corresponding individual ingredients. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) at 7.5 μg/mL concentration and T. cordifolia water extract (T.C-1) at 2.5 μg/mL concentration showed 36.46% and 8.92% inhibition of Histamine release, respectively. The composition-1 (C-1) containing these two ingredients (Gly-2 and T.C-1) in the ratio of 3:1 at 10 μg/mL showed a 62.29% inhibition of Histamine release, which is significantly higher than the additive effect of 45.41% (36.46%+8.92%) calculated from the inhibition of Histamine release shown by the corresponding individual ingredients (Table 23). The other compositions 2-44 (C-2 to C-44) also showed synergistic inhibition of Histamine release as summarized in Tables 23-27.
- Hence, these compositions (C-1 to C-44) unexpectedly showed better efficacy in increasing the production of IFN-γ and IL-2 and inhibiting LTB4; and increasing Histamine release when compared to their corresponding individual ingredients. Thus, the compositions comprising a first ingredient Glycyrrhiza glabra extract containing metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; have the tendency to show synergism when the corresponding individual ingredients are combined.
- Process: The inventors achieved two methods for the preparation of these compositions; (i) neutralization of Glycyrrhiza glabra extract with corresponding metal compound(s); (ii) purifying the extract through cation exchange resin and then conducting neutralization as summarized below in FIG. 2.
- A second method, i.e., preparation of zinc/potassium double salt of glycyrrhizin, is achieved by a novel method. Purified glycyrrhizic acid is obtained by passing the 50% aqueous ethanol extract of G. glabra root through a cation exchange resin column. Glycyrrhizic acid thus obtained is neutralized with a metal oxide such as zinc oxide followed by metal carbonate such as potassium carbonate or metal hydroxide such as potassium hydroxide or mixtures thereof to yield zinc/potassium double salt of glycyrrhizin (Gly-3).
- Thus, the process for the preparation of synergistic compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof: and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; wherein the process comprises the following steps of,
-
- (i) extracting dried Glycyrrhiza glabra root powder with suitable solvent;
- (ii) optionally passing the extract solution from step (i) through a cation exchange resin;
- (iii) neutralizing the solution of step (i) or step (ii) with metal compound(s);
- (iv) filtering the solution;
- (v) evaporating the solvent and drying the residue to obtain Glycyrrhiza glabra extract containing metal salt of glycyrrhizin;
- (vi) blending Glycyrrhiza glabra extract containing metal salt of glycyrrhizin in step (v) with at least one extract derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally in the presence of pharmaceutically or nutraceutically or dietically acceptable excipients, carriers, and diluents; and
- (vii) drying the product under a vacuum to get the compositions.
- The suitable solvent used in the process for the preparation of the extracts or fractions or phytochemicals or mixtures thereof is selected from; C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol; ketones selected from acetone, methylisobutyl ketone; chlorinated solvents selected from methylene dichloride and chloroform; water and mixtures thereof, C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof. The metal used in the process for the preparation of the compositions is selected from zinc and potassium, and the metal compound used for the preparation of these compositions is in the form of their metal salts, metal oxides, metal hydroxides, or carbonates.
- Examples include but are not limited to zinc oxide, zinc carbonate, zinc hydroxide, potassium hydroxide, and potassium carbonate. The cation exchange resin used in the process for the preparation of the compositions is selected from strong and weak cation exchange resins, which include but not limited to Tulson T 42, Tulson CXO 12, Dowex marathon, Indion 225, Indion 236, Indion 730, Indion 652, Diaion SK1B, Diaion PK216, C 100, C 104, C 107, C 800 LT, C 800 MP, C 145, CG 10, D 001, Amberlite IRC 86, WK 11, WK 40L, D113.
- Formulations: The present invention also provides synergistic herbal compositions comprising; the first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin, and mixtures thereof, and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally with at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- The synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; wherein the composition may be formulated with at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose; wherein the pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents are selected from monosaccharide's such as glucose, dextrose, fructose, galactose etc.; disaccharides such as but not limited to sucrose, maltose, lactose, lactulose, trehalose cellobiose, chitobiose etc.; polycarbohydrates such as starch and modified starch such as sodium starch glycolate, pre-gelatinized starch, soluble starch, and other modified starches; dextrins that are produced by hydrolysis of starch or glycogen such as yellow dextrin, white dextrin, maltodextrin etc.; polyhydric alcohols or sugar alcohols such as but not limited to sorbitol, mannitol, inositol, xylitol, isomalt etc.; cellulose based derivatives such as but not limited to microcrystalline cellulose, hydroxy propyl methyl cellulose, hydroxy ethyl cellulose etc.; silicates such as but not limited to neusilin, veegum, talc, colloidal silicon dioxide etc.; metallic stearates such as but not limited to calcium stearate, magnesium stearate, zinc stearate etc.; organic acids such as citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid etc.; fatty acid esters and esters of poly sorbate, natural gums such as but not limited to acacia, carrageenan, guar gum, xanthan gum etc.; vitamin B group, nicotinamide, calcium pantothenate, amino acids, proteins such as but not limited to casein, gelatin, pectin, agar; organic metal salts such as but not limited to sodium chloride, calcium chloride, dicalcium phosphate, zinc sulphate, zinc chloride etc.; natural pigments, flavors, class I & class II preservatives and aqueous, alcoholic, hydro-alcoholic, organic solutions of above listed ingredients alone or in combination.
- In-vivo study of the compositions for airway allergic inflammation and immune modulation in ovalbumin-induced C57BL/6 mice: The compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; were evaluated for modulation of inflammation and immune response in ovalbumin-induced mice.
- Allergic airway inflammation (AAI) is a serious global health concern affecting the mucosal tissue of the nasal cavity. The AAI is caused due to allergens, which are responsible for the induction of hypersensitivity reactions in the affected individuals. The allergens are any chemical or agent found indoor or outdoor, such as dust, mites, pollens, paints, molds, etc., to induce a cascade of inflammatory reactions mediated via the allergen-specific immunoglobulins. Acute activation and infiltration of inflammatory cells, which include neutrophils, lymphocytes, mast cells, eosinophils, into the bronchial fluid and in the lungs, are the most characteristic features in airway inflammation. These inflammatory cells, upon recruitment, lead to the production of various inflammatory mediators.
- Ovalbumin-induced allergic airway inflammation in mice is a well-established and widely studied experimental model to study airway inflammation and immunomodulation. In ovalbumin (OVA)-induced animals, CD4+ T cells play a major role in the initiation and maintenance of T helper cell, type 2 (Th2)-like allergic airway inflammation, that is characterized by increased number of eosinophil count (eosinophilia). CD4+ T-cells play an important role in cell-mediated immune protection. CD4+ T cells produce Th2 cytokines that enhance immunoglobulin E (IgE) production and eosinophil accumulation. Therefore, a treatment that modulates the humoral immune response to suppress IgE production may be useful in reducing allergic reactions in inflammatory immune diseases, including allergic airway inflammation and other microbial infections. OVA induction causes increased accumulation of inflammatory cells that include neutrophil (neutrophilia), eosinophil in the bronchiolar lavage fluid in animals. In allergic airway inflammation, an increased level of mast cells in the lungs is an essential characteristic feature. Mast cells produce histamine. Histamine is a potent inflammatory mediator associated with allergic reactions, promoting vascular and tissue changes and promotes inflammatory cells migration. Mast cells also mediate systemic immunosuppression induced by platelet-activating factors via the histamine-dependent mechanism. Therefore, a treatment that reduces the number of mast cells can decrease the inflammatory and allergic reactions and elicit an immune response in the body. Further, the experimental evidence suggests that interferon-gamma (IFN-γ) alleviates allergic airway inflammation and elicits an immune response in the host. In the majority, IFN-γ is produced from CD4+ T cells during the adaptive immune response and is essential for controlling bacterial or viral infection and host cells' survival.
- Thus the effect of T. cordifolia water extract (T.C-1), G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2), and their composition (Comp-45) on some of the major biomarkers that modulate inflammation and immune responses were explored in OVA-induced C57BL/6 experimental mice. The present observations reveal that the mice supplemented with the inventive compositions showed synergistic improvements in the modulation of the biomarkers such as Total Leucocytes, Neutrophils, Lymphocytes, and Eosinophils; serum interferon-gamma (IFN-γ) and IgE; inflammatory cells and mast cells; and CD4+ T-cell subset as summarized in Tables 28-32.
- Decrease of Total Leucocytes, Neutrophils, Lymphocytes, and Eosinophils: The present compositions showed synergistic efficacy in decreasing Total Leucocytes, Neutrophils, Lymphocytes, and Eosinophils in the experimental animals. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 36.4% and 30.3% decreases in total Leucocytes respectively from OVA-induced mice. Comp-45 containing these two extracts at 2:1 ratio showed a 54.5% decrease from the OVA-induced mice, which is a significantly higher decrease than the corresponding individual ingredients, suggesting a synergistic effect between G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in decreasing total Leucocytes (Table 28). Similarly, comp-45 also showed significantly higher decreases than the corresponding individual ingredients in the number of Neutrophils, Lymphocytes, and Eosinophils, as summarized in Tables 28 & 29.
- Increase in serum interferon-gamma (IFN-γ) and decrease in IgE: The present compositions showed synergistic efficacies in modulating serum interferon-gamma (IFN-γ) and IgE in the experimental animals. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 17.6% and 14.0% increase in IFN-γ respectively from OVA-induced mice. Comp-45 containing these two extracts at 2:1 ratio showed a 24.2% increase from the OVA-induced mice, which is a significantly higher increase than the corresponding individual ingredients, suggesting a synergistic effect between G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in increasing IFN-γ. Similarly, comp-45 also showed a significantly higher decrease than the corresponding individual ingredients in IgE, as summarized in Table 30.
- Decrease in inflammatory cells and mast cells in the lungs: The present compositions showed synergistic efficacy in decreasing of inflammatory cells and mast cells in the lungs of experimental animals. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 38.7% and 29.0% decrease in total inflammation score (presence of peribroncheal+perivascular PMN cells), respectively from OVA-induced mice. Comp-45 containing these two extracts at 2:1 ratio showed a 51.6% decrease from the OVA-induced mice, which is a significantly higher decrease than the corresponding individual ingredients, suggesting a synergistic effect between G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in decreasing total inflammation score. Similarly, comp-45 also showed a significantly higher decrease in mast cells than the corresponding individual ingredients, as summarized in Table 31.
- Increase in CD4+ and CD8+ T-cell subsets in the spleen: The present compositions showed synergistic efficacy in increasing the CD4+ and CD8+ T-cell populations in the spleen of the experimental animals. For example, G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) supplemented animals showed 10.1% and 4.8% increase in CD4+ T-cell subset, respectively, from OVA-induced mice. Comp-45 containing these two extracts at 2:1 ratio showed a 17.6% increase from the OVA-induced mice, which is a significantly higher increase than the corresponding individual ingredients, suggesting a synergistic effect between G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia water extract (T.C-1) in increasing the CD4+ T-cell population in the spleen. Similarly, comp-45 also showed a significantly higher increase than the corresponding individual ingredients, as summarized in Table 32.
- The foregoing demonstrates that synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from the extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; unexpectedly showed better efficacy in increasing the production of IFN-γ and IL-2, and inhibition of LTB4 and histamine release; when compared to their corresponding individual ingredients. Hence, the said compositions can be useful for ameliorating immunity, lung function, and respiratory health.
- Therefore, in an important embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthen natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
- In one preferred embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing zinc salt of glycyrrhizin; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for improving immunity, respiratory health that include allergic airway inflammation, cold and cough.
- In one preferred embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing potassium salt of glycyrrhizin; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for improving immunity, respiratory health that include allergic airway inflammation, cold and cough.
- In one preferred embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for improving immunity, respiratory health that include allergic airway inflammation, cold and cough.
- In another embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; wherein glycyrrhizin can be in the range of 2.0-50% and zinc can be in the range of 0.1-5.0% and potassium can be in the range of 0.1-10.0%.
- In another embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; wherein the concentration of Glycyrrhiza glabra extract containing metal salt in the composition varies in the range of 10%-90% by weight and the concentration of the extract of Tinospora cordifolia or Zingiber officinale or Justicia adhatoda or Ocimum sanctum; in the composition varies in the range of 90%-10% by weight.
- In another embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; wherein the extracts or fractions or phytochemicals or mixtures thereof are obtained from at least one plant part selected from the group comprising leaves, stems, tender stems, tender twigs, aerial parts, whole fruit, fruit peel rind, seeds, flower heads, root, bark, hardwood, rhizome or whole plant or mixtures thereof.
- In another embodiment, the present invention provides synergistic herbal compositions as disclosed above; wherein the extract, fraction, phytochemical or mixtures thereof, are produced using at least one solvent selected from C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol; ketones selected from acetone, methylisobutyl ketone, chlorinated solvents selected from methylene dichloride and chloroform; water and mixtures thereof; C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
- In another embodiment, the present invention provides synergistic herbal compositions as described above; wherein the extract, fraction or mixtures thereof, in the composition are standardized to at least one phytochemical reference marker compound or pharmacologically active marker; wherein phytochemical marker compound or group of phytochemical compounds is in the concentration range of 0.01% to 90% by weight of the extract.
- In another embodiment, the present invention provides synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin, and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- In another embodiment, the present invention provides method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing the said human with an effective dose of a composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof, and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
- In another embodiment, the present invention provides the use of a synergistic herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthen natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
- In another embodiment of the invention, the composition as disclosed above is formulated into a dosage form selected from dry powder form, liquid form, beverage, food product, dietary supplement, or any suitable form such as a tablet, a capsule, a soft chewable tablet or gummy bear.
- In another embodiment of the invention, the composition as disclosed above can be formulated into nutritional/dietary supplements that can be contemplated/made into the dosage form of healthy foods, or food for specified health uses such as solid food like chocolate or nutritional bars, semisolid food like cream, jam, or gel or beverage such as refreshing beverage, lactic acid bacteria beverage, drop, candy, chewing gum, gummy candy, yoghurt, ice cream, pudding, soft adzuki bean jelly, jelly, cookie, tea, soft drink, juice, milk, coffee, cereal, snack bar and the like.
- In another embodiment of the invention, the composition as disclosed above can be formulated into controlled-release tablets, using controlled release polymer-based coatings by the techniques including nanotechnology, microencapsulation, colloidal carrier systems and other drug delivery systems for obtaining the desired therapeutic benefit.
- Those of ordinary skilled in the art will appreciate that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments or examples disclosed herein, but is intended to cover modifications within the objectives and scope of the present invention as defined in the specification. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present disclosure, as many variations thereof possible without departing from the spirit of the disclosure.
- To dried root powder of G. glabra (400 g) was added 50% aqueous ethanol (3.2 L) and the mixture was extracted at ambient temperature for 2 h. The mixture was filtered and the extraction process was repeated with 50% aqueous ethanol (2×2.4 L). The combined 50% aqueous ethanol extract was evaporated under reduced pressure up to 1.6 L of volume and the concentrate was diluted with water (1.6 L). Zinc oxide (2.16 g) and potassium carbonate were added in succession at 1 h interval, and the mixture was stirred at ambient temperature for 2 h. The mixture was filtered through celite, and the filtrate was evaporated under reduced pressure to give the product (Gly-2) as a brown color solid (114 g).
- Method-2 (Gly-3): The 50% aq ethanol extract prepared from 50 g of G. glabra dried root powder as described in method 1 was passed through a strong cation exchange resin (T-42H+) column. The column was further eluted with 50% aqueous ethanol (400 mL). The acidic fractions were collected and mixed to give the total eluent. To the total eluent was added potassium carbonate (610 mg), zinc oxide (270 mg), potassium carbonate (300 mg), and potassium hydroxide (120 mg) in succession at 1 h intervals. The mixture was stirred at ambient temperature for 1 h, filtered, and the filtrate was evaporated under reduced pressure to give the product as a pale brown color solid (13.0 g).
- For comparison, G. glabra extract was prepared using the following procedure: G. glabra dried root powder (50 g) was extracted with 50% aqueous ethanol as described in example 1, and evaporation of the extract gave the product as a brown color solid (13.5 g).
- To the total acidic eluent fraction obtained from 100 g of G. glabra dried root powder, as in example 1 was added zinc oxide (540 mg). The mixture was stirred at ambient temperature for 2 h, filtered, and the filtrate was evaporated under reduced pressure to give the product as a pale brown color solid (27 g).
- G. glabra extract containing potassium salt was prepared from G. glabra dried root powder (50 g) as described in example 2 by replacing zinc oxide with potassium carbonate (915 mg) or potassium hydroxide or mixtures thereof, to give the product as a pale brown color solid (13.4 g).
- The G. glabra extracts containing metal salts disclosed above were analyzed for glycyrrhizic acid by analytical HPLC. The concentration of metals such as zinc, and potassium were analyzed by ICP-MS, and the results are summarized in Table 3.
-
TABLE 3 Analysis data of Glycyrrhiza glabra extracts containing metal salts Example Glycyrrhizic Metal (%) by # Product description acid by HPLC ICP-MS 1 (Method- Zinc and potassium 14.88% Zn: 0.9%; 1) K: 2.5% 1 (Method- double salt 15.64% Zn: 1.2%; 2) K: 3.2% 1A Without metal salt/s 12.71% — 2 Zinc salt 14.12% Zn: 1.4% 3 Potassium salt 14.25% K: 3.5% - To dried stem powder of T. cordifolia (100 g) was added water (250 mL), and the mixture was extracted at ambient temperature for 3 h. The mixture was filtered, and the extraction process was repeated with water (5×250 mL) under similar conditions. The combined water extract was evaporated under reduced pressure to give the product as a brown color solid (7.5 g).
- 50% Aqueous ethanol extract of T. cordifolia (100 g) was prepared as described in example 5 by replacing water with 50% aq ethanol to give the product as a brown color solid (8.3 g).
- Ethanol extract of T. cordifolia (100 g) was prepared as described in example 5 by replacing water with ethanol to give the product as a brown color solid (2.1 g).
- The various extracts of T. cordifolia were standardized to 8-hydroxytinosporide by the analytical HPLC method, and the results are summarized in Table 4.
-
TABLE 4 Details of Tinospora cordifolia extracts Example Solvent for 8-hydroxytinosporide # extraction by HPLC 5 Water 0.25% 6 50% aqueous ethanol 0.40% 7 Ethanol 0.55% - The dried rhizome powder of Z. officinale was extracted using prior art procedures to give Z. officinale oleoresin. The extract was analyzed for total gingerols, and shogaols by HPLC method of analysis and found that the extract contains 30% of total gingerols and shogaols.
- Z. officinale oleoresin obtained above is further formulated using excipients such as zinc glycinate, xantham gum, Ultrasperse-A, magnesium hydroxide, MCC and syloid in a suitable solvent to get the product, which contains 5% of total zingerols and shogaols.
- To dried rhizome powder of Z. officinale (100 g) was added 90% aqueous ethanol (700 mL), and the mixture was extracted at ambient temperature for 1 h. The mixture was filtered, and the extraction process was repeated twice with 90% aqueous ethanol (2×500 mL) under similar conditions. The combined 90% aqueous ethanol extract was evaporated under reduced pressure to give the product as a pale brown color thick paste (10.1 g).
- The various extracts of Z. officinale were standardized to total gingerols and shogaols by the analytical HPLC method, and the results are summarized in Table 5.
-
TABLE 5 Details of Zingiber officinale extracts Example Solvent for Total of gingerols and # extraction shogaols by HPLC 9 Prior art procedure 30% 10 Formulation with 5% excipients 11 90% aq ethanol 17.5% - To dried leaf powder of Justicia adhatoda (1.0 Kg) was added 70% aqueous methanol (9.0 L), and the mixture was extracted at ambient temperature for 3 h. The mixture was filtered, and the extraction process was repeated with 70% aqueous methanol (3×7.0 L) under similar conditions. The combined 70% aqueous methanol extract was evaporated under reduced pressure to give the product as a brown color solid (100 g).
- Ethanol extract of J. adhatoda (100 g) was prepared as described in example 13 by replacing 70% aq methanol with ethanol to give the product as a brown color solid (5.6 g).
- The dried aerial parts powder of J. adhatoda (100 g) was extracted with 70% aqueous methanol as described in example 13. The product was further enriched by acidifying with 3% aqueous citric acid solution (700 mL) and washed with chloroform to remove impurities. The acidic solution was basified with ammonia solution, and the solution was extracted with chloroform. The organic layer was evaporated to give the alkaloid fraction (1.2 g), which contains majorly vasicine.
- The various extracts of J. adhatoda were standardized to vasicine by the analytical HPLC method, and the results are summarized in Table 6.
-
TABLE 6 Details of of Justicia adhatoda extracts Example # Solvent for extraction Vasicine by HPLC 13 70% aq methanol 1.45% 14 Ethanol 2.80% 15 Enriched extract 95.50% - To dried aerial parts, powder of O. sanctum (100 g) was added 70% aqueous methanol (900 mL), and the mixture was stirred at ambient temperature for 1 h. The mixture was filtered, and the extraction process was repeated with 70% aqueous methanol (2×700 mL) under similar conditions. The combined 70% aqueous methanol extract was evaporated under reduced pressure to give the product as a pale green color solid (10 g).
- 90% Aq ethanol extract of O. sanctum (100 g) was prepared as described in example 17 by replacing 70% aq methanol with 90% aq ethanol to give the product as a pale brown color solid (9.0 g).
- The various extracts of O. sanctum were standardized to total oleanolic acid and ursolic acid by the analytical HPLC method, and the results are summarized in Table 7.
-
TABLE 7 Details of Ocimum sanctum extracts Solvent for Total oleanolic acid and Example # extraction ursolic acid by HPLC 17 70% aq methanol 1.40% 18 90% aq ethanol 6.56% -
-
- Composition-1 (C-1): C-1 was prepared by combining Gly-2 and T.C-1 in the ratio of 3:1.
- Composition-2 (C-2): C-2 was prepared by combining Gly-2 and T.C-1 in the ratio of 2:1.
- Composition-3 (C-3): C-3 was prepared by combining Gly-2 and T.C-1 in the ratio of 1:1.
- Composition-4 (C-4): C-4 was prepared by combining Gly-2 and T.C-1 in the ratio of 1:2.
- Composition-5 (C-5): C-5 was prepared by combining Gly-2 and T.C-1 in the ratio of 1:3.
- Composition for comparison (comp-2A): The composition-2A was prepared by combining G. glabra extract (Gly-1) and T. cordifolia water extract (T.C-1) in the ratio of 2:1.
-
-
- Composition-6 (C-6): C-6 was prepared by combining Gly-2 and Z.O-2 in the ratio of 4:1.
- Composition-7 (C-7): C-7 was prepared by combining Gly-2 and Z.O-2 in the ratio of 3:1.
- Composition-8 (C-8): C-8 was prepared by combining Gly-2 and Z.O-2 in the ratio of 2:1.
- Composition-9 (C-9): C-9 was prepared by combining Gly-2 and Z.O-2 in the ratio of 1:1.
- Composition-10 (C-10): C-10 was prepared by combining Gly-2 and Z.O-2 in the ratio of 1:2.
- Composition-11 (C-11): C-11 was prepared by combining Gly-2 and Z.O-2 in the ratio of 1:3.
- Composition for comparison (comp-7A): The composition-7A was prepared by combining G. glabra extract (Gly-1) and Z. officinale oleoresin-2 (Z.O-2) in the ratio of 3:1.
-
-
- Composition-12 (C-12): C-12 was prepared by combining Gly-2 and T.C-2 in the ratio of 2:1.
- Composition-13 (C-13): C-13 was prepared by combining Gly-2 and T.C-2 in the ratio of 1:1.
- Composition-14 (C-14): C-14 was prepared by combining Gly-2 and T.C-2 in the ratio of 1:2.
-
-
- Composition-15 (C-15): C-15 was prepared by combining Gly-2 and Z.O-3 in the ratio of 2:1.
- Composition-16 (C-16): C-16 was prepared by combining Gly-2 and Z.O-3 in the ratio of 1:1.
- Composition-17 (C-17): C-17 was prepared by combining Gly-2 and Z.O-3 in the ratio of 1:2.
-
-
- Composition-18 (C-18): C-18 was prepared by combining Gly-2 and J.A-1 in the ratio of 2:1.
- Composition-19 (C-19): C-19 was prepared by combining Gly-2 and J.A-1 in the ratio of 1:1.
- Composition-20 (C-20): C-20 was prepared by combining Gly-2 and J.A-1 in the ratio of 1:2.
-
-
- Composition-21 (C-21): C-21 was prepared by combining Gly-2 and O.S-1 in the ratio of 2:1.
- Composition-22 (C-22): C-22 was prepared by combining Gly-2 and O.S-1 in the ratio of 1:1.
- Composition-23 (C-23): C-23 was prepared by combining Gly-2 and O.S-1 in the ratio of 1:2.
-
-
- Composition-24 (C-24): C-24 was prepared by combining Gly-4 and T.C-1 in the ratio of 2:1.
- Composition-25 (C-25): C-25 was prepared by combining Gly-4 and T.C-1 in the ratio of 1:1.
- Composition-26 (C-26): C-26 was prepared by combining Gly-4 and T.C-1 in the ratio of 1:2.
-
-
- Composition-27 (C-27): C-27 was prepared by combining Gly-4 and Z.O-2 in the ratio of 2:1.
- Composition-28 (C-28): C-28 was prepared by combining Gly-4 and Z.O-2 in the ratio of 1:1.
- Composition-29 (C-29): C-29 was prepared by combining Gly-4 and Z.O-2 in the ratio of 1:2.
-
-
- Composition-30 (C-30): C-30 was prepared by combining Gly-4 and J.A-3 in the ratio of 2:1.
- Composition-31 (C-31): C-31 was prepared by combining Gly-4 and J.A-3 in the ratio of 1:1.
- Composition-32 (C-32): C-32 was prepared by combining Gly-4 and J.A-3 in the ratio of 1:2.
-
-
- Composition-33 (C-33): C-33 was prepared by combining Gly-4 and O.S-2 in the ratio of 2:1.
- Composition-34 (C-34): C-34 was prepared by combining Gly-4 and O.S-2 in the ratio of 1:1.
- Composition-35 (C-35): C-35 was prepared by combining Gly-4 and O.S-2 in the ratio of 1:2.
-
-
- Composition-36 (C-36): C-36 was prepared by combining Gly-5 and T.C-3 in the ratio of 2:1.
- Composition-37 (C-37): C-37 was prepared by combining Gly-5 and T.C-3 in the ratio of 1:1.
- Composition-38 (C-38): C-38 was prepared by combining Gly-5 and T.C-3 in the ratio of 1:2.
-
-
- Composition-39 (C-39): C-39 was prepared by combining Gly-5 and Z.O-1 in the ratio of 2:1.
- Composition-40 (C-40): C-40 was prepared by combining Gly-5 and Z.O-1 in the ratio of 1:1.
- Composition-41 (C-41): C-41 was prepared by combining Gly-5 and Z.O-1 in the ratio of 1:2.
-
-
- Composition-42 (C-42): C-42 was prepared by combining Gly-5 and J.A-2 in the ratio of 2:1.
- Composition-43 (C-43): C-43 was prepared by combining Gly-5 and J.A-2 in the ratio of 1:1.
- Composition-44 (C-44): C-44 was prepared by combining Gly-5 and J.A-2 in the ratio of 1:2.
-
-
- Composition-45 (C-45): A mixture of G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2, 63.33 g), T. cordifolia water extract (T.C-1, 31.66 g), Glucidex12D (3.0 g), and Syloid (2.0 g) was taken in a double poly bag and blend manually. The powder was pulverized and sieved through 40 mesh to give the composition as a free-flowing fine powder (Comp-45).
- Composition-46 (C-46): A mixture of G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2, 78.4 g), Z. officinale oleoresin-2 (Z.O-2, 19.6 g), and Syloid (2.0 g) was taken in a double poly bag and blend manually. The powder was pulverized and sieved through 40 mesh to give the composition as a free-flowing fine powder (Comp-46).
- Human blood was collected from healthy volunteers from a peripheral vein with a syringe containing EDTA at a final concentration of 2 mM. Plasma was separated by centrifugation at 150×g for 10 min, and the residual blood was diluted with RPMI medium supplemented with 10% FBS and 2 mM EDTA at a ratio of 1:3. Thirty milliliters of blood were carefully layered onto 15 mL of Ficoll/Lymphoprep in a 50 mL falcon tube in the dark, and tubes were centrifuged at 350×g for 30 min. The buffy coat (interface between medium and Ficoll) containing peripheral blood mononuclear cells (PBMC) was collected carefully in 25 mL of cold 1× phosphate-buffered saline (PBS) and centrifuged at 1200 rpm for 10 min. Residual RBCs found in PBMCs pellet were removed by treating with ACK lysis buffer (Gibco, USA) and washed with fresh 1×PBS. PBMC were seeded in a 96-well plate with a density of 0.1×106 cells/well and treated with different concentrations of test samples. Cells with 0.2% DMSO served as vehicle control. The plate was incubated in a CO2 incubator at 37° C. for 2 hrs. Finally, cells were induced with the combination of Phorbol-12-myristate-13-acetate (PMA, 7.5 nM) and Phytohemagglutinin-A (PHA, 2 μg/ml) for 4 hrs except for vehicle control by keeping the plate at 37° C. in a CO2 incubator. The plate was centrifuged at 270×g for 5 min, and 120 μL cell-free supernatants were collected. Quantification of IFN-7 was performed using the ELISA kit (R&D Systems, USA) according to the manufacturer's instructions. Absorbance was measured at 450 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA). Percent increase in IFN-γ production was calculated using the following formula.
-
- The results are presented in Tables: 8-12.
-
TABLE 8 Percent increase in IFN-γ production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Tinospora cordifolia water extract (T.C-1) Gly-2 T.C-1 % Increase in IFN-γ production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-1 7.5 13.64 2.5 3.01 3:1 10 16.65 23.49 C-2 6.67 12.13 3.33 4.01 2:1 10 16.14 23.18 C-3 5.0 9.09 5.0 6.02 1:1 10 15.11 21.09 C-4 3.33 6.05 6.67 8.03 1:2 10 14.08 21.7 C-5 2.5 4.55 7.5 9.03 3:1 10 13.58 20.23 -
TABLE 9 Percent increase in IFN-γ production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Zingiber officinale oleoresin-2 (Z.O-2) Gly-2 Z.O-2 % Increase in IFN-γ production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-6 8.0 14.54 2.0 3.00 4:1 10 17.54 22.69 C-7 7.5 13.64 2.5 3.75 3:1 10 17.38 22.87 C-8 6.67 12.13 3.33 4.99 2:1 10 17.12 23.98 C-9 5.0 9.09 5.0 7.50 1:1 10 16.59 22.75 C-10 3.33 6.05 6.67 10.00 1:2 10 16.05 21.33 C-11 2.5 4.55 7.5 11.24 3:1 10 15.79 22.53 -
TABLE 10 Percent increase in IFN-γ production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia 50% aq ethanol extract (T.C-2) or Z. officinale 90% aq ethanol extract (Z.O-3) or J. adhatoda 70% aq methanol extract (J.A-1) or O. sanctum 70% aq methanol extract (O.S-1) Gly-2 T.C-2 % Increase in IFN-γ production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-12 6.67 12.13 3.33 3.05 2:1 10 15.18 19.34 C-14 3.33 6.05 6.67 6.11 1:2 10 12.16 18.58 Gly-2 Z.O-3 C-15 6.67 12.13 3.33 4.52 2:1 10 16.64 21.5 C-17 3.33 6.05 6.67 9.05 1:2 10 15.11 19.45 Gly-2 J.A-1 C-18 6.67 12.13 3.33 2.79 2:1 10 14.92 19.29 C-20 3.33 6.05 6.67 5.60 1:2 10 11.65 15.23 Gly-2 O.S-1 C-21 6.67 12.13 3.33 2.40 2:1 10 14.53 18.15 C-23 3.33 6.05 6.67 4.82 1:2 10 10.87 14.51 -
TABLE 11 Percent increase in IFN-γ production by the compositions of Glycyrrhiza glabra extract containing zinc salt of glycyrrhizin (Gly-4) and T. cordifolia water extract (T.C-1) or Z. officinale oleoresin-2 (Z.O-2) or J. adhatoda enriched extract (J.A-3) or O. sanctum 90% aq ethanol extract (O.S-2) Gly-4 T.C-1 % Increase in IFN-γ production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-24 6.67 11.47 3.33 4.01 2:1 10 15.48 19.96 C-26 3.33 5.73 6.67 8.03 1:2 10 13.76 18.77 Gly-4 Z.O-2 C-27 6.67 11.47 3.33 4.99 2:1 10 16.46 21.23 C-29 3.33 5.73 6.67 10.00 1:2 10 15.73 19.35 Gly-4 J.A-3 C-30 6.67 11.47 3.33 2.87 2:1 10 14.34 17.85 C-32 3.33 5.73 6.67 5.75 1:2 10 11.48 15.09 Gly-4 O.S-2 C-33 6.67 11.47 3.33 3.49 2:1 10 14.97 19.19 C-35 3.33 5.73 6.67 7.00 1:2 10 12.72 18.58 -
TABLE 12 Percent increase in IFN-γ production by the compositions of Glycyrrhiza glabra extract containing potassium salt of glycyrrhizin (Gly-5) and T. cordifolia ethanol extract (T.C-3) or Z. officinale oleoresin-1 (Z.O-1) or J. adhatoda ethanol extract (J.A-2) Gly-5 T.C-3 % Increase in IFN-γ production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-36 6.67 11.67 3.33 2.82 2:1 10 14.49 18.15 C-38 3.33 5.82 6.67 5.65 1:2 10 11.47 15.64 Gly-5 Z.O-1 C-39 6.67 11.67 3.33 4.32 2:1 10 15.98 20.75 C-41 3.33 5.82 6.67 8.65 1:2 10 14.48 18.53 Gly-5 J.A-2 C-42 6.67 11.67 3.33 2.89 2:1 10 14.56 18.14 C-44 3.33 5.82 6.67 5.79 1:2 10 11.61 15.33 - An equal number of Jurkat cells (0.1×106) suspended in 200 μL of RPMI medium supplemented with 10% FBS was seeded in each well of a 96-well plate. Cells were pretreated with different concentrations of test samples. Cells with 0.2% DMSO served as vehicle control. The plate was incubated in a CO2 incubator at 37° C. for 2 hrs. After the incubation period, the cells were induced with the combination of Phorbol-12-myristate-13-acetate (PMA, 7.5 nM) and Phytohemagglutinin-A (PHA, 0.5 μg/ml) for 4 hrs except for vehicle control by keeping the plate at 37° C. in a CO2 incubator. The plate was centrifuged at 270×g for 5 min to collect the cell-free culture supernatants. Quantitation of IL-2 was performed using the ELISA kit (R&D systems Cat #DY202) according to the manufacturer's instructions. Absorbance was measured at 450 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA). Percent increase in IL-2 production was calculated using the following formula.
-
- The results are presented in Tables: 13-17.
-
TABLE 13 Percent increase in IL-2 production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Tinospora cordifolia water extract (T.C-1) Gly-2 T.C-1 % Increase in IL-2 production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-1 7.5 9.70 2.5 2.43 3:1 10 12.13 16.23 C-2 6.67 8.62 3.33 3.24 2:1 10 11.86 15.96 C-3 5.0 6.47 5.0 4.86 1:1 10 11.33 14.57 C-4 3.33 4.31 6.67 6.48 1:2 10 10.79 13.65 C-5 2.5 3.23 7.5 7.29 3:1 10 10.52 14.37 -
TABLE 14 Percent increase in IL-2 production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly- 2) and Zingiber officinale oleoresin-2 (Z.O-2) Gly-2 Z.O-2 % Increase in IL-2 production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-6 8.0 10.34 2.0 1.66 4:1 10 12.00 16.34 C-7 7.5 9.70 2.5 2.07 3:1 10 11.77 15.86 C-8 6.67 8.62 3.33 2.76 2:1 10 11.38 14.56 C-9 5.0 6.47 5.0 4.15 1:1 10 10.61 15.05 C-10 3.33 4.31 6.67 5.53 1:2 10 9.84 14.03 C-11 2.5 3.23 7.5 6.22 3:1 10 9.45 13.07 -
TABLE 15 Percent increase in IL-2 production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia 50% aq ethanol extract (T.C-2) or Z. officinale 90% aq ethanol extract (Z.O-3) or J. adhatoda 70% aq methanol extract (J.A-1) or O. sanctum 70% aq methanol extract (O.S-1) Gly-2 T.C-2 % Increase in IL-2 production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-12 6.67 8.62 3.33 2.02 2:1 10 10.65 13.43 C-14 3.33 4.31 6.67 4.05 1:2 10 8.35 10.45 Gly-2 Z.O-3 C-15 6.67 8.62 3.33 2.21 2:1 10 10.84 13.63 C-17 3.33 4.31 6.67 4.44 1:2 10 8.74 11.73 Gly-2 J.A-1 C-18 6.67 8.62 3.33 2.82 2:1 10 11.44 14.35 C-20 3.33 4.31 6.67 5.64 1:2 10 9.95 12.89 Gly-2 O.S-1 C-21 6.67 8.62 3.33 2.67 2:1 10 11.29 14.08 C-23 3.33 4.31 6.67 5.34 1:2 10 9.65 13.26 -
TABLE 16 Percent increase in IL-2 production by the compositions of Glycyrrhiza glabra extract containing zinc salt of glycyrrhizin (Gly-4) and T. cordifolia water extract (T.C-1) or Z. officinale oleoresin-2 (Z.O-2) or J. adhatoda enriched extract (J.A-3) or O. sanctum 90% aq ethanol extract (O.S-2) Gly-4 T.C-1 % Increase in IL-2 production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-24 6.67 6.82 3.33 3.24 2:1 10 10.05 12.91 C-26 3.33 3.40 6.67 6.48 1:2 10 9.89 13.25 Gly-4 Z.O-2 C-27 6.67 6.82 3.33 2.76 2:1 10 9.58 12.55 C-29 3.33 3.40 6.67 5.53 1:2 10 8.93 12.18 Gly-4 J.A-3 C-30 6.67 6.82 3.33 2.99 2:1 10 9.80 13.17 C-32 3.33 3.40 6.67 5.98 1:2 10 9.39 12.10 Gly-4 O.S-2 C-33 6.67 6.82 3.33 3.14 2:1 10 9.96 12.49 C-35 3.33 3.40 6.67 6.30 1:2 10 9.70 12.26 -
TABLE 17 Percent increase in IL-2 production by the compositions of Glycyrrhiza glabra extract containing potassium salt of glycyrrhizin (Gly-5) and T. cordifolia ethanol extract (T.C-3) or Z. officinale oleoresin-1 (Z.O-1) or J. adhatoda ethanol extract (J.A-2) Gly-5 T.C-3 % Increase in IL-2 production Comp % % Dose Additive # μg/mL increase μg/mL increase Ratio μg/mL (Calculated) Observed C-36 6.67 7.14 3.33 2.45 2:1 10 9.58 12.17 C-38 3.33 3.56 6.67 4.90 1:2 10 8.47 10.82 Gly-5 Z.O-1 C-39 6.67 7.14 3.33 2.76 2:1 10 9.90 12.48 C-41 3.33 3.56 6.67 5.54 1:2 10 9.10 11.73 Gly-5 J.A-2 C-42 6.67 7.14 3.33 3.23 2:1 10 10.36 13.63 C-44 3.33 3.56 6.67 6.46 1:2 10 10.03 13.01 - Example 36: Assay for Leukotriene B4 (LTB4) inhibition Human blood was collected from healthy volunteers from a peripheral vein with a syringe containing EDTA at a final concentration of 2 mM. Plasma was separated by centrifugation at 1000 rpm for 10 min, and the residual blood was diluted with RPMI medium supplemented with 10% FBS and 2 mM EDTA at a ratio of 1:3. Thirty milliliters of blood was carefully layered onto 15 mL of Ficoll/Lyymphoprep in a 50 mL falcon tube in the dark, and the tubes were centrifuged at 350×g for 30 min. After removing the peripheral blood mononuclear cells (PBMC) and Ficoll/Lymphoprep, the settled RBC layer containing granulocytes was treated with ACK lysis buffer (Gibco Cat #A10492-01) to lyse the RBC completely. After centrifugation at 150×g for 10 min, the resulting cell pellet of polymorphonuclear leukocytes (PMNs) was resuspended in RPMI containing 1% (v/v) newborn calf serum (NBCS). An equal number of PMNs (50,000 cells) was seeded in each well of a 96-well plate and treated with different concentrations of the test samples. Cells with 0.2% DMSO were served as vehicle control. The plate was incubated in a CO2 incubator at 37° C. for 2 hrs. Finally, cells were induced with 10 μM A23187 (Sigma Chemical Co, USA) for 10 min, except the vehicle control cells. The plate was centrifuged at 150×g for 5 min, and 120 μL of cell-free supernatants were collected. Quantitation of LTB4 in the cell culture supernatants was performed using an LTB4 ELISA kit (R&D Systems, USA) according to the manufacturer's instructions. Absorbance was measured at 450 nm with a correction wavelength of 570 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA). Percent reduction in LTB4 production was calculated using the following formula.
-
- The results are presented in Tables: 18-22.
-
TABLE 18 Percent inhibition in LTB4 production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Tinospora cordifolia water extract (T.C-1) Gly-2 T.C-1 % Inhibition in LTB4 Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-1 7.5 18.49 2.5 4.61 3:1 10 23.10 31.98 C-2 6.67 16.44 3.33 6.14 2:1 10 22.58 32.87 C-3 5.0 12.33 5.0 9.22 1:1 10 21.55 33.09 C-4 3.33 8.21 6.67 12.30 1:2 10 20.51 31.62 C-5 2.5 6.16 7.5 13.83 3:1 10 19.99 29.45 -
TABLE 19 Percent inhibition in LTB4 production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly- 2) and Zingiber officinale oleoresin-2 (Z.O-2) Gly-2 Z.O-2 % Inhibition in LTB4 Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-6 8.0 19.72 2.0 4.11 4:1 10 23.83 32.3 C-7 7.5 18.49 2.5 5.14 3:1 10 23.62 31.1 C-8 6.67 16.44 3.33 6.84 2:1 10 23.28 29.88 C-9 5.0 12.33 5.0 10.27 1:1 10 22.60 31.36 C-10 3.33 8.21 6.67 13.70 1:2 10 21.91 28.31 C-11 2.5 6.16 7.5 15.41 3:1 10 21.57 29.16 -
TABLE 20 Percent inhibition in LTB4 production by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia 50% aq ethanol extract (T.C-2) or Z. officinale 90% aq ethanol extract (Z.O-3) or J. adhatoda 70% aq methanol extract (J.A-1) or O. sanctum 70% aq methanol extract (O.S-1) Gly-2 T.C-2 % Inhibition in LTB4 Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-12 6.67 16.44 3.33 4.33 2:1 10 20.77 27.48 C-14 3.33 8.21 6.67 8.68 1:2 10 16.89 23.52 Gly-2 Z.O-3 C-15 6.67 16.44 3.33 6.15 2:1 10 22.59 29.43 C-17 3.33 8.21 6.67 12.31 1:2 10 20.52 29.86 Gly-2 J.A-1 C-18 6.67 16.44 3.33 6.19 2:1 10 22.63 28.37 C-20 3.33 8.21 6.67 12.40 1:2 10 20.61 26.91 Gly-2 O.S-1 C-21 6.67 16.44 3.33 5.53 2:1 10 21.97 27.91 C-23 3.33 8.21 6.67 11.07 1:2 10 19.28 26.52 -
TABLE 21 Percent inhibition in LTB4 production by the compositions of Glycyrrhiza glabra extract containing zinc salt of glycyrrhizin (Gly-4) and T. cordifolia water extract (T.C-1) or Z. officinale oleoresin-2 (Z.O-2) or J. adhatoda enriched extract (J.A-3) or O. sanctum 90% aq ethanol extract (O.S-2) Gly-4 T.C-1 % Inhibition in LTB4 Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-24 6.67 14.88 3.33 6.14 2:1 10 21.02 26.05 C-26 3.33 7.43 6.67 12.30 1:2 10 19.73 24.9 Gly-4 Z.O-2 C-27 6.67 14.88 3.33 6.84 2:1 10 21.72 28.37 C-29 3.33 7.43 6.67 13.70 1:2 10 21.13 25.84 Gly-4 J.A-3 C-30 6.67 14.88 3.33 6.19 2:1 10 21.07 26.78 C-32 3.33 7.43 6.67 12.40 1:2 10 19.83 24.83 Gly-4 O.S-2 C-33 6.67 14.88 3.33 4.80 2:1 10 19.68 24.82 C-35 3.33 7.43 6.67 9.62 1:2 10 17.05 24.32 -
TABLE 22 Percent inhibition in LTB4 production by the compositions of Glycyrrhiza glabra extract containing potassium salt of glycyrrhizin (Gly-5) and T. cordifolia ethanol extract (T.C-3) or Z. officinale oleoresin-1 (Z.O-1) or J. adhatoda ethanol extract (J.A-2) Gly-5 T.C-3 % Inhibition in LTB4 Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-36 6.67 14.04 3.33 5.01 2:1 10 19.05 24.5 C-38 3.33 7.01 6.67 10.03 1:2 10 17.04 22.42 Gly-5 Z.O-1 C-39 6.67 14.04 3.33 5.45 2:1 10 19.49 24.59 C-41 3.33 7.01 6.67 10.92 1:2 10 17.93 22.94 Gly-5 J.A-2 C-42 6.67 14.04 3.33 4.33 2:1 10 18.37 22.89 C-44 3.33 7.01 6.67 8.68 1:2 10 15.69 19.77 - Primary rat peritoneal cells (RPCs) were utilized for the histamine release assay. Fifty milliliters of sterile Tyrode buffer was injected into the peritoneal cavity of an anesthetized rat, and the buffer containing RPCs was recovered using a sterile Pasteur pipette. The recovered RPCs were passed through a cell strainer to remove residual tissue, washed with Tyrode buffer, and centrifuged at 400×g for 10 min at 4° C. In a 96-well plate, RPCs (0.1×106 cells/well) were seeded. The cells were pretreated with different concentrations of test samples and incubated at 37° C. in a CO2 incubator for 2 hr. Next, cells were induced with 2.5 μM of A23187 (Sigma Chemical Co, USA) at 37° C. in a CO2 incubator for 15 min. Cells with 0.2% DMSO served as vehicle control. The plate was centrifuged at 270×g for 5 min to collect the cell-free culture supernatants. Twenty microliters of 1N NaOH were added to all wells of a 96-well black clear bottom plate. To this plate, 100 μl of the cell-free supernatants were added, followed by 5 μl of O-Phthalaldehyde (OPA), and incubated for 3 min on a shaker in the dark. The reaction was stopped with 10 μl of stop solution (3N HCl) and mixed the content thoroughly. Relative fluorescence (RFU) was measured at Ex/Em: 360/440 nm in a microplate reader (Spectramax 2e, Molecular Devices, USA) for estimating the spontaneous histamine release. Percent reduction of spontaneous histamine release from the primary peritoneal cells was calculated using the following formula.
-
- The results are presented in Tables: 23-27.
-
TABLE 23 Percent inhibition in histamine release by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Tinospora cordifolia water extract (T.C-1) Gly-2 T.C-1 % Inhibition in histamine Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-1 7.5 36.48 2.5 8.92 3:1 10 45.41 62.29 C-2 6.67 32.44 3.33 11.89 2:1 10 44.33 62.61 C-3 5.0 24.32 5.0 17.85 1:1 10 42.17 63.19 C-4 3.33 16.20 6.67 23.81 1:2 10 40.01 59.23 C-5 2.5 12.16 7.5 26.77 3:1 10 38.93 56.82 -
TABLE 24 Percent inhibition in histamine release by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and Zingiber officinale oleoresin-2 (Z.O-2) Gly-2 Z.O-2 % Inhibition in histamine Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-6 8.0 38.91 2.0 6.61 4:1 10 45.53 62.34 C-7 7.5 36.48 2.5 8.27 3:1 10 44.75 61.76 C-8 6.67 32.44 3.33 11.01 2:1 10 43.46 60.35 C-9 5.0 24.32 5.0 16.54 1:1 10 40.86 61.39 C-10 3.33 16.20 6.67 22.06 1:2 10 38.26 57.92 C-11 2.5 12.16 7.5 24.80 3:1 10 36.96 56.16 -
TABLE 25 Percent inhibition in histamine release by the compositions of Glycyrrhiza glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2) and T. cordifolia 50% aq ethanol extract (T.C-2) or Z. officinale 90% aq ethanol extract (Z.O-3) or J. adhatoda 70% aq methanol extract (J.A-1) or O. sanctum 70% aq methanol extract (O.S-1) Gly-2 T.C-2 % Inhibition in histamine Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-12 6.67 32.44 3.33 9.71 2:1 10 42.15 57.08 C-14 3.33 16.20 6.67 19.45 1:2 10 35.64 48.54 Gly-2 Z.O-3 C-15 6.67 32.44 3.33 10.12 2:1 10 42.56 55.30 C-17 3.33 16.20 6.67 20.26 1:2 10 36.46 53.79 Gly-2 J.A-1 C-18 6.67 32.44 3.33 10.60 2:1 10 43.04 54.89 C-20 3.33 16.20 6.67 21.22 1:2 10 37.42 50.95 Gly-2 O.S-1 C-21 6.67 32.44 3.33 10.35 2:1 10 42.79 53.16 C-23 3.33 16.20 6.67 20.73 1:2 10 36.93 51.93 -
TABLE 26 Percent inhibition in histamine release by the compositions of Glycyrrhiza glabra extract containing zinc salt of glycyrrhizin (Gly-4) and T. cordifolia water extract (T.C-1) or Z. officinale oleoresin-2 (Z.O-2) or J. adhatoda enriched extract (J.A-3) or O. sanctum 90% aq ethanol extract (O.S-2) Gly-4 T.C-1 % Inhibition in histamine Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-24 6.67 28.93 3.33 11.89 2:1 10 40.82 53.10 C-26 3.33 14.44 6.67 23.81 1:2 10 38.25 51.76 Gly-4 Z.O-2 C-27 6.67 28.93 3.33 11.01 2:1 10 39.94 55.12 C-29 3.33 14.44 6.67 22.06 1:2 10 36.50 53.34 Gly-4 J.A-3 C-30 6.67 28.93 3.33 10.32 2:1 10 39.25 51.48 C-32 3.33 14.44 6.67 20.67 1:2 10 35.12 47.35 Gly-4 O.S-2 C-33 6.67 28.93 3.33 10.55 2:1 10 39.48 56.00 C-35 3.33 14.44 6.67 21.13 1:2 10 35.57 54.99 -
TABLE 27 Percent inhibition in histamine release by the compositions of Glycyrrhiza glabra extract containing potassium salt of glycyrrhizin (Gly-5) and T. cordifolia ethanol extract (T.C-3) or Z. officinale oleoresin-1 (Z.O-1) or J. adhatoda ethanol extract (J.A-2) Gly-5 T.C-3 % Inhibition in histamine Comp % % Dose Additive # μg/mL inhibition μg/mL inhibition Ratio μg/mL (Calculated) Observed C-36 6.67 28.61 3.33 11.53 2:1 10 40.13 51.29 C-38 3.33 14.28 6.67 23.09 1:2 10 37.37 49.61 Gly-5 Z.O-1 C-39 6.67 28.61 3.33 10.64 2:1 10 39.24 49.07 C-41 3.33 14.28 6.67 21.30 1:2 10 35.58 48.03 Gly-5 J.A-2 C-42 6.67 28.61 3.33 9.71 2:1 10 38.32 48.41 C-44 3.33 14.28 6.67 19.45 1:2 10 33.73 44.61 - Decrease in total Leucocytes, Neutrophils, Lymphocytes, and Eosinophils: Modulations of airway allergic inflammation and immune response by the test samples were evaluated in ovalbumin (OVA, Sigma Chemicals, USA) induced 8-9 weeks old (20-25 g body weight) male C57BL/6 mice. The animals were acclimatized for five days, and then they were randomized and allocated into Group-1 (G1) to Group-5 (G5) based on their body weights (BW). Each group contained eight animals (n=8). Mice in G1 and G2 received Carboxymethylcellulose (CMC) as a vehicle, and G3-G5 received 100 mg per kg BW of T.C-1, Gly-2, and comp-45 mixed with CMC through oral gavage for 12 days. On day 1, each mice in G2-G5 was sensitized with 100 μg OVA in 200 μL alum adjuvant via the intraperitoneal route. These animals were given intranasal challenges with 100 μg OVA (in 50 μL sterile 1×PBS) on day 8, and 50 μg OVA (in 50 L 1×PBS) on days 10 and 12 under mild anesthesia. The G1 or vehicle control animals received equivalent volumes of sterile PBS on the days of OVA sensitization and challenges. On day 12, blood samples were collected under mild anesthesia for estimation of serum interferon-gamma (IFN-γ) and immunoglobulin E (IgE). Post blood collection, respective animals were euthanized using an overdose of thiopentone sodium, followed by exsanguination, and subjected to necropsy. Bronchoalveolar lavage fluid (BALF), spleen, and lung tissues were collected. Total Leucocyte Count (TLC) and Differential Leucocyte Count (DLC) (neutrophils, lymphocytes, and eosinophil) were performed from BALF; the spleen was processed for analysis of CD4 and CD8 cells using flow cytometry. One lobe of the lung tissue was fixed in formalin for gross pathology and microscopic examinations.
- Serum biomarker analysis (IFN-γ and IgE): The levels of IFN-γ and IgE in the rat serum samples were analyzed using enzyme-linked immunosorbent assay (ELISA) kits. Briefly, 100 μL of respective samples/standards were added to respective wells of the pre-coated 96-well ELISA plates and incubated for 2.5 hours at room temperature. After the incubation, the plates were washed with 1× wash buffer; 100 μL of 1× prepared detection antibody was added and incubated for 1 hour at room temperature with gentle shaking. After washing the wells, 100 μL Streptavidin solution was added; the plate was sealed and incubated for 45 minutes at room temperature with gentle shaking. After wash, TMB substrate was added; plates were sealed and incubated for 30 minutes in the dark at room temperature with gentle shaking. In each well, fifty microliters of stop solution were added, and absorbance was measured at 450 nm using a microplate reader (Spectramax2e, Molecular Devices, San Jose, CA). The levels of IFN-γ and IgE were quantified utilizing the respective standard curves generated for the respective analyte.
- CD4 and CD8 cell population analysis in splenocytes: The spleens of the experimental mice were gently crushed on Falcon® 100 μm sterile cell strainers (Corning, USA) using 1×RPMI medium to obtain single cells suspension of splenocytes. The splenocytes were counted, and 0.3×106 splenocytes suspended in FACS buffer were taken into each well of a ‘v’ bottom 96-well plate and processed for flow cytometry staining. The cells were washed with FACS buffer and incubated 70 ng of PE anti-mouse CD4 Antibody (BioLegend, USA) and 70 ng of APC anti-mouse CD8a Antibody (BioLegend, USA) for 30 minutes in the dark at room temperature. After the incubation, the cells were washed with FACS buffer and fixed using 100 μL of BD Cytofix™ Fixation Buffer (BD Biosciences, USA) for 20 minutes in the dark. After incubation, the cells were washed with FACS buffer and resuspended in the same buffer and acquired on BD FACSVerse flow cytometer for analysis. Percent positive CD4+ and CD8+ populations were recorded.
- Histopathology examinations: The lung tissues were fixed in 0% neutral buffered formalin for 48 hours in the dark at room temperature. The fixed tissues were embedded in paraffin and the paraffin-embedded tissues were sectioned at 4-micron sizes in a rotary microtome. The tissue sections were stained with hematoxylin-eosin and toluidine blue to examine the inflammatory cells and mast cells, respectively. The stained tissue sections were examined under 10× objective of a light microscope (Axio scope Al, Carl Zeiss, Germany). For each parameter, one hundred random fields were examined. The results are presented in Tables: 28-32.
-
TABLE 28 Percent decrease in total Leucocytes and Neutrophils count in bronchoalveolar lavage (BAL) fluid of the experimental mice supplemented with G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2), T. cordifolia water extract (T.C-1), or their composition in 2:1 ratio (Comp-45) Total Leucocytes Neutrophils % decrease Differential % decrease from count % from Experimental Count OVA- of total OVA- group (103/mL) induced Lucocytes) induced Vehicle control 0.6 — 2.2 — (G1) OVA-induced 1.7 — 22.4 — (G2) OVA + T.C-1 1.2 30.3 17.1 23.5 (G3) OVA + Gly-2 1.1 36.4 14.6 34.6 (G4) OVA + Comp-45 0.8 54.5 9.8 56.4 (G5) -
TABLE 29 Percent decrease in Lymphocytes and Eosinophil count in bronchoalveolar lavage (BAL) fluid of the experimental mice supplemented with G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2), T. cordifolia water extract (T.C-1), or their composition in 2:1 ratio (Comp-45) Lymphocytes Eosinophils Differential % Differential % count decrease count decrease (% of from (% of from Experimental total OVA- total OVA- group Leucocytes) induced Leucocytes) induced Vehicle control 3.8 — 0.3 — (G1) OVA-induced 5.6 — 5.5 — (G2) OVA + T.C-1 4.6 17.8 3.3 40.9 (G3) OVA + Gly-2 4.4 22.2 2.9 47.7 (G4) OVA + Comp-45 4.0 28.9 2.0 63.6 (G5) -
TABLE 30 Percent increase in serum interferon-gamma (IFN-γ) and percent decrease in serum IgE of the experimental mice supplemented with G. glabra extract containing zinc/ potassium double salt of glycyrrhizin (Gly-2), T. cordifolia water extract (T.C-1), or their composition in 2:1 ratio (Comp-45) Serum IFN-γ Serum IgE Mean % increase Mean % decrease Experimental concn from OVA- concn from OVA- group (pg/mL) induced (mg/mL) induced Vehicle control 37.0 — 0.4 — (G1) OVA-induced 25.2 — 1.9 — (G2) OVA + T.C-1 28.8 14.0 1.7 10.8 (G3) OVA + Gly-2 29.7 17.6 1.6 15.0 (G4) OVA + 31.3 24.2 1.2 38.5 Comp-45 (G5) -
TABLE 31 Percent decrease in inflammatory cells and mast cells count in the lungs of the experimental mice supplemented with G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2), T. cordifolia water extract (T.C- 1), or their composition in 2:1 ratio (Comp-45) Total inflammation score (peribronchial + perivascular PMN cells) Mast cells % decrease % decrease Experimental Mean from OVA- Mean from OVA- group count induced count induced Vehicle control 0.0 — 1.2 — (G1) OVA-induced (G2) 3.9 — 2.5 — OVA + T.C-1 (G3) 2.8 29.0 2.1 15.0 OVA + Gly-2 (G4) 2.4 38.7 1.8 30.0 OVA + Comp-45 1.9 51.6 1.5 40.0 (G5) -
TABLE 32 Percent increase in CD4+ and CD8+ T-cell subsets in the spleen of the experimental mice supplemented with G. glabra extract containing zinc/potassium double salt of glycyrrhizin (Gly-2), T. cordifolia water extract (T.C-1), or their composition in 2:1 ratio (Comp-45) T cell subsets in spleen Mean Mean population % increase population % increase Experimental of CD4+ from OVA- of CD8+ from OVA- group cells (%) induced cells (%) induced Vehicle control 20.0 — 10.4 — (G1) OVA-induced 15.7 — 10.0 — (G2) OVA + T.C-1 16.4 4.8 10.1 0.9 (G3) OVA + Gly-2 17.2 10.1 10.3 3.4 (G4) OVA + Comp-45 18.4 17.6 10.7 7.6 (G5) - It is evident from the above experimental data that the compositions (C-1 to C-44) of the present invention unexpectedly showed synergistic efficacy in increasing the production of IFN-γ (tables 8-12) and IL-2 (tables 13-17) and in inhibiting the production of LTB4(Tables 18-22); and in inhibiting Histamine release (tables 23-27) when compared to their corresponding individual ingredients. Further it also well established that the compositions (C-1 to C-44) of the present invention unexpectedly showed synergistic efficacy in decreasing the total Leucocytes and Neutrophils (table 28); decreasing in Lymphocytes and Eosinophil (table 29) count in bronchoalveolar lavage (BAL) fluid; increasing serum interferon-gamma (IFN-γ) production and decreasing serum IgE (table 30) in experimental mice when compared to individual ingredients. Furthermore, it is demonstrated by the present inventors that the compositions (C-1 to C-44) of the present invention decreases inflammatory cells and mast cells count in the lungs (table 31) and increases the count in CD4+ and CD8+ T-cell subsets (table 32) in the spleen of the experimental mice.
- Therefore, the synergistic compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; are useful for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
Claims (17)
1. Synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; for obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose.
2. The synergistic herbal compositions as claimed in claim-1, wherein the concentration of Glycyrrhiza glabra extract containing metal salt varies in the range of 10%-90% by weight and the concentration of the extract, fraction, phytochemical or mixtures thereof of the second ingredient selected from Tinospora cordifolia or Zingiber officinale or Justicia adhatoda or Ocimum sanctum; varies in the range of 90%-10% by weight.
3. The synergistic herbal compositions as claimed in claim-1, wherein the metal salt(s) of glycyrrhizin consists glycyrrhizin in the range of 2.0-50% and zinc in the range of 0.1-5.0% and potassium in the range of 0.1-10.0%.
4. The synergistic herbal compositions as claimed in claim-1, wherein the extract, fraction or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; are standardized to at least one phytochemical reference marker compound or pharmacologically active marker; wherein phytochemical marker compound or group of phytochemical compounds is in the concentration range of 0.01% to 90% by weight of the extract.
5. The synergistic herbal compositions as claimed in claim-1, wherein the extracts or fractions or phytochemicals or mixtures thereof are obtained from at least one plant part selected from the group comprising leaves, stems, tender stems, tender twigs, aerial parts, whole fruit, fruit peel rind, seeds, flower heads, root, bark, hardwood, rhizome or whole plant or mixtures thereof.
6. The synergistic herbal compositions as claimed in claim-1, wherein the extract, fraction, phytochemical or mixtures thereof; are produced using at least one solvent selected from C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol; ketones selected from acetone, methylisobutyl ketone, chlorinated solvents selected from methylene dichloride and chloroform; water and mixtures thereof; C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
7. The synergistic herbal compositions as claimed in claim-1, further contain optionally at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers, and diluents.
8. The synergistic herbal compositions as claimed in claim-7, wherein the pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents are selected from monosaccharide's such as glucose, dextrose, fructose, galactose etc.; disaccharides such as but not limited to sucrose, maltose, lactose, lactulose, trehalose cellobiose, chitobiose, Glucidex 12D etc.; polycarbohydrates such as starch and modified starch such as sodium starch glycolate, pre-gelatinized starch, soluble starch, and other modified starches, ultrasperse A; dextrins that are produced by hydrolysis of starch or glycogen such as yellow dextrin, white dextrin, maltodextrin etc.; polyhydric alcohols or sugar alcohols such as but not limited to sorbitol, mannitol, inositol, xylitol, isomalt etc.; cellulose based derivatives such as but not limited to microcrystalline cellulose, hydroxy propyl methyl cellulose, hydroxy ethyl cellulose etc.; silicates such as but not limited to neusilin, veegum, talc, colloidal silicon dioxide, syloid etc.; metallic stearates such as but not limited to calcium stearate, magnesium stearate, zinc stearate etc.; organic acids such as citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid etc.; fatty acid esters and esters of poly sorbate, natural gums such as but not limited to acacia, carrageenan, guar gum, xanthan gum etc.; vitamin B group, nicotinamide, calcium pantothenate, amino acids, proteins such as but not limited to casein, gelatin, pectin, agar; organic metal salts such as but not limited to sodium chloride, calcium chloride, dicalcium phosphate, zinc sulphate, zinc chloride etc.; natural pigments, flavors, class I & class II preservatives and aqueous, alcoholic, hydro-alcoholic, organic solutions of above listed ingredients alone or in combination.
9. The synergistic herbal compositions as claimed in claim 1 , wherein the composition is formulated into a dosage form selected from dry powder form, liquid form, beverage, food product, dietary supplement, or any suitable form such as a tablet, a capsule, a soft chewable tablet or gummy bear.
10. The synergistic herbal compositions as claimed in claim 1 , wherein the composition is formulated into nutritional/dietary supplements that can be contemplated/made into the dosage form of healthy foods, or food for specified health uses such as solid food like chocolate or nutritional bars, semisolid food like cream, jam, or gel or beverage such as refreshing beverage, lactic acid bacteria beverage, drop, candy, chewing gum, gummy candy, yogurt, ice cream, pudding, soft adzuki bean jelly, jelly, cookie, tea, soft drink, juice, milk, coffee, cereal, snack bar.
11. The synergistic herbal compositions as claimed in claim 1 , wherein the composition is formulated into controlled-release tablets, using controlled release polymer-based coatings by the techniques including nanotechnology, microencapsulation, colloidal carrier systems and other drug delivery systems for obtaining the desired therapeutic benefit.
12. A process for preparing synergistic herbal compositions comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, the potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally contains at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents; wherein the process comprises the following steps of;
(i) extracting dried Glycyrrhiza glabra root powder with suitable solvent;
(ii) optionally passing the extract solution from step (i) through a cation exchange resin;
(iii) neutralizing the solution of step (i) or step (ii) with metal compound(s);
(iv) filtering the solution;
(v) evaporating the solvent and drying the residue to obtain Glycyrrhiza glabra extract containing metal salt of glycyrrhizin;
(vi) blending Glycyrrhiza glabra extract containing metal salt of glycyrrhizin in step (v) with at least one extract derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum;
optionally in the presence of pharmaceutically or nutraceutically or dietically acceptable excipients, carriers, and diluents; and
(vii) drying the product under a vacuum to get the compositions.
13. The process for preparing synergistic compositions as claimed in claim-12, wherein the suitable solvent used in the process for the preparation of the extracts or fractions or phytochemicals or mixtures thereof are produced by using at least one solvent selected from; C1-C5 alcohols selected from ethanol, methanol, n-propanol, isopropyl alcohol; ketones selected from acetone, methylisobutyl ketone; chlorinated solvents selected from methylene dichloride and chloroform; water and mixtures thereof; C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
14. The process for preparing synergistic compositions as claimed in claim-12, wherein the metal is selected from zinc and potassium; and the metal compound used for the preparation of these compositions is in the form of their metal salts, metal oxides, metal hydroxides or carbonates; selected but not limited to zinc oxide, zinc carbonate, zinc hydroxide, potassium hydroxide, and potassium carbonate.
15. The process for preparing synergistic compositions as claimed in claim-12, wherein the cation exchange resin is selected from but not limited to Tulson T 42, Tulson CXO 12, Dowex marathon, Indion 225, Indion 236, Indion 730, Indion 652, Diaion SK1B, Diaion PK216, C 100, C 104, C 107, C 800 LT, C 800 MP, C 145, CG 10, D 001, Amberlite IRC 86, WK 11, WK 40L and D113.
16. Method of obtaining at least one health benefit selected from improving immunity/eliciting immune response/rejuvenating the immune system; improving symptoms associated with innate immunity, adaptive immunity, cellular immunity and humoral immunity; strengthening natural defense, preventing viral respiratory infections, improving lung function, supporting respiratory health, and treating/alleviating symptoms associated with airway inflammation and allergic rhinitis that include cold, cough, runny, and itchy nose in a human; wherein the method comprises supplementing human with an effective dose of a herbal composition comprising a first ingredient Glycyrrhiza glabra extract containing at least one metal salt of glycyrrhizin selected from zinc salt of glycyrrhizin, potassium salt of glycyrrhizin, zinc/potassium double salt of glycyrrhizin and mixtures thereof; and a second ingredient selected from extract, fraction, phytochemical or mixtures thereof derived from Tinospora cordifolia, Zingiber officinale, Justicia adhatoda, and Ocimum sanctum; optionally containing at least one component selected from pharmaceutically or nutraceutically or dietically acceptable excipients, carriers and diluents.
17. (canceled)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202041041718 | 2020-09-25 | ||
IN202041041718 | 2020-09-25 | ||
PCT/IN2021/050937 WO2022064525A1 (en) | 2020-09-25 | 2021-09-24 | "synergistic herbal compositions for immunity, cold and cough" |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230364173A1 true US20230364173A1 (en) | 2023-11-16 |
Family
ID=80845586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/246,768 Pending US20230364173A1 (en) | 2020-09-25 | 2021-09-24 | Synergistic herbal compositions for immunity, cold and cough |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230364173A1 (en) |
EP (1) | EP4216975A1 (en) |
WO (1) | WO2022064525A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891221A (en) * | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
US7838037B2 (en) * | 1999-11-17 | 2010-11-23 | Tagra Biotechnologies Ltd. | Method of microencapsulation |
US20030228383A1 (en) * | 2002-06-06 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals, Ltd. | Herbal cough formulations and process for the preparation thereof |
DE60220958T2 (en) * | 2002-12-30 | 2008-04-10 | Council Of Scientific And Industrial Research | DEVELOPMENT OF A HUSTENSTILLEN AND ANTI-INFLAMMATORY FORMULATION FROM HERBS |
US7344738B2 (en) * | 2005-11-28 | 2008-03-18 | Sahajanand Biotech Pvt. Ltd. | Herbal composition for treatment of immunocompromised conditions |
US20100112101A1 (en) * | 2008-05-06 | 2010-05-06 | Laila Impex | Bio-availability/bio-efficacy enhancing activity of stevia rebaudiana and extracts and fractions and compounds thereof |
CN101928324B (en) * | 2010-08-27 | 2013-04-10 | 江苏天晟药业有限公司 | Potassium glycyrrhizinate preparation method |
CA3058301A1 (en) * | 2017-03-29 | 2018-10-04 | Benny Antony | Medicinal composition derived from multiple plant sources for gastrointestinal disorder |
-
2021
- 2021-09-24 US US18/246,768 patent/US20230364173A1/en active Pending
- 2021-09-24 WO PCT/IN2021/050937 patent/WO2022064525A1/en unknown
- 2021-09-24 EP EP21871859.1A patent/EP4216975A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4216975A1 (en) | 2023-08-02 |
WO2022064525A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zorofchian Moghadamtousi et al. | Loranthus micranthus Linn.: biological activities and phytochemistry | |
JP6623253B2 (en) | Pharmaceutical composition for prevention or treatment of chronic obstructive pulmonary disease (COPD) comprising Pistachia Weinmannifolia extract, a fraction thereof or a compound isolated therefrom | |
KR102006738B1 (en) | Pharmaceutical Composition comprising extracts of Justicia procumbens L. for prevention or treatment of respiratory diseases | |
JP6381818B2 (en) | Composition comprising an extract or fraction of a genus Fox | |
KR100860080B1 (en) | Pharmaceutical composition comprising the plant extract belonged to Veronica genus having anti-inflammatory, anti-allergic and-asthmatic activity | |
JP2008531584A (en) | Composition comprising the genus Matabia and method of using the same | |
KR101486484B1 (en) | A food composition for the improvement or prevention of asthma comprising extract of allium hookeri | |
KR20190043996A (en) | Composition for prevention or treatment respiratory diseases comprising Chrysanthemum morifolium Ramatuelle extract and Scutellaria baicalensis extract as an active ingredient | |
KR101336094B1 (en) | Functional food composition for improving skin condition and preparation method thereof | |
KR101604347B1 (en) | Pharmaceutical composition comprising an extract or a fraction of Pistacia weinmannifolia J. Poiss. Ex Franch for preventing or treating inflammatory-related diseases | |
US20230364173A1 (en) | Synergistic herbal compositions for immunity, cold and cough | |
KR101879596B1 (en) | Composition for preventing, improving or treating respiratory inflammatory disease comprising Chamaecyparis obtusa essential oil as effective component | |
KR20150083327A (en) | Composition comprising an extract or a fraction of Euonymus alatus for preventing or treating asthma | |
JP2010070531A (en) | DEGRANULATION INHIBITOR OBTAINED FROM NATURAL EXTRACT, beta-HEXOSAMINIDASE RELEASE INHIBITOR, ANTIALLERGIC OR ANTIINFLAMMATORY FOOD, DRUG, ANIMAL FEED COMPOSITION AND COSMETIC RAW MATERIAL COMPOSITION | |
US20230293620A1 (en) | Synergistic herbal compositions for immune boosting and respiratory health | |
WO2012111934A2 (en) | Pharmaceutical composition for preventing and treating inflammatory disease or asthma containing an extract of decaspermum fruticosum | |
KR20140026091A (en) | Composition comprising mosla chinensis maxim(labiatae) extract for preventing or treating inflammatory allergic disease | |
KR102366763B1 (en) | Food composition for improvement of respiratory health | |
KR101150485B1 (en) | A pharmaceutical composition comprising extract of Alchornea triplinervia for prevention and treatment of asthma or inflammatory diseases | |
KR20230134448A (en) | Composition for improvement of respiratory health containing complex extracts of Humulus japonicus as an active ingredient | |
KR20230098052A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Lysimachia mauritiana extract as effective component | |
KR20220142004A (en) | A food composition for the improvement or prevention of asthma comprising extract of ginseng berry | |
JP2021528107A (en) | Composition for prevention, amelioration, or treatment of respiratory diseases containing Luo Han Guo extract as an active ingredient | |
KR20070011137A (en) | A composition comprising tiarellic acid having anti-inflammatory, anti-allergic and anti-asthmatic activity | |
Moghadamtousi et al. | Activities and Phytochemistry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
AS | Assignment |
Owner name: LAILA NUTRACEUTICALS, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOKARAJU, GANGA RAJU;GOKARAJU, VENKATA KANAKA RANGA RAJU;BHUPATHIRAJU, KIRAN;AND OTHERS;REEL/FRAME:065745/0454 Effective date: 20231122 |